Earnings Release • Aug 9, 2024
Earnings Release
Open in ViewerOpens in native device viewer


This half year report release is unaudited. The comparison figures in brackets refer to the corresponding period in the previous year.
1) The following items have been excluded from the comparison period revenue: the divestment of dental care services, the transfer of cost liability for demanding specialised care, the gradual termination of Jämsän Terveys' service agreement, other changes to outsourcing agreements and COVID-19 services. 2) Alternative performance measure. In addition to the IFRS figures, Pihlajalinna presents additional, alternative performance indicators which the company monitors internally and which provide the company's management, investors, stock market analysts and other stakeholders with important additional information concerning the company's financial performance, financial position and cash flows. These performance indicators should not be reviewed separately from the IFRS figures and they should not be considered to replace the IFRS figures.
| 4–6/2024 | 4–6/2023 | 1–6/2024 | 1–6/2023 | ||||
|---|---|---|---|---|---|---|---|
| 3 months | 3 months | change % | 6 months | 6 months | change % | 2023 | |
| INCOME STATEMENT | |||||||
| Revenue, EUR million | 174.8 | 183.6 | -4.8 | 358.0 | 371.4 | -3.6 | 720.0 |
| EBITDA, EUR million | 22.7 | 17.7 | 27.8 | 48.3 | 40.8 | 18.6 | 72.5 |
| EBITDA, % | 13.0 | 9.7 | 13.5 | 11.0 | 10.1 | ||
| Adjusted EBITDA, EUR million ¹⁾ | 22.7 | 18.0 | 26.2 | 48.6 | 39.4 | 23.5 | 80.6 |
| Adjusted EBITDA, % ¹⁾ | 13.0 | 9.8 | 13.6 | 10.6 | 11.2 | ||
| Adjusted operating profit before the amortisation and impairment of intangible assets (EBITA), EUR million ¹⁾ |
11.4 | 7.3 | 56.7 | 26.3 | 18.3 | 43.6 | 37.8 |
| Adjusted operating profit before the amortisation and impairment of intangible assets (EBITA), % ¹⁾ |
6.5 | 4.0 | 7.3 | 4.9 | 5.2 | ||
| Operating profit (EBIT), EUR million | 9.5 | 4.9 | 93.9 | 22.2 | 15.4 | 44.2 | 20.6 |
| Operating profit (EBIT), % | 5.5 | 2.7 | 6.2 | 4.2 | 2.9 | ||
| Adjusted operating profit (EBIT), EUR million ¹⁾ | 9.6 | 5.1 | 22.5 | 14.0 | 60.4 | 29.1 | |
| Adjusted operating profit (EBIT), % ¹⁾ | 5.5 | 2.8 | 6.3 | 3.8 | 4.0 | ||
| Profit before tax (EBT), EUR million | 6.7 | 2.4 | 173.9 | 16.9 | 9.9 | 70.7 | 8.2 |
| SHARE-RELATED INFORMATION | |||||||
| Earnings per share (EPS), EUR | 0.19 | 0.07 | 190.1 | 0.49 | 0.31 | 59.7 | 0.19 |
| Equity per share, EUR | 6.94 | 6.69 | 3.9 | 6.56 | |||
| OTHER KEY FIGURES | |||||||
| Return on capital employed (ROCE), % | 5.5 | 4.2 | 30.9 | 4.0 | |||
| Return on equity (ROE), % | 6.9 | 7.8 | -11.4 | 3.4 | |||
| Equity ratio, % | 24.3 | 22.1 | 10.0 | 22.0 | |||
| Gearing, % | 211.0 | 236.4 | -10.8 | 243.9 | |||
| Interest-bearing net debt, EUR million | 325.1 | 354.1 | -8.2 | 352.7 | |||
| Net debt/adjusted EBITDA, 12 months ¹⁾ | 3.6 | 5.0 | -28.2 | 4.4 | |||
| Gearing, excluding IFRS 16, % | 75.8 | 95.7 | -20.7 | 94.38 | |||
| Interest-bearing net debt excluding IFRS 16, EUR million | 122.1 | 147.9 | -17.4 | 142.0 | |||
| Net debt/adjusted EBITDA, excluding IFRS 16, 12 months ¹⁾ | 2.0 | 3.4 | -40.9 | 2.7 | |||
| Gross investments, EUR million ²⁾ | 16.0 | 14.7 | 23.0 | 36.4 | -36.9 | 66.5 | |
| Cash flow from operating activities, EUR million | 27.5 | 27.3 | 0.8 | 58.7 | 46.3 | 26.8 | 79.0 |
| Cash flow after investments, EUR million | 21.6 | 22.3 | 50.0 | 35.4 | -41.4 | 60.5 | |
| Average number of personnel (FTE) | 4,753 | 4,978 | -4.5 | 4,923 | |||
| Personnel at the end of the period (NOE) | 6,721 | 7,479 | -10.1 | 6,880 | |||
| Practitioners at the end of the period | 2,124 | 2,121 | 0.1 | 2,208 | |||
| NPS, Private Healthcare Services | 85.3 | 78.2 | 83.6 | 77.9 | 7.32 | 78.2 | |
| NPS, Public Services | 78.8 | 73.5 | 78.3 | 72.1 | 8.60 | 75.5 |
1) Significant transactions that are not part of the normal course of business, are related to business acquisition or divestment costs (IFRS 3), are infrequently occurring events or valuation items that do not affect cash flow are treated as adjustment items affecting comparability between financial years. According to Pihlajalinna's definition, such items include, for example, restructuring measures, impairment of assets and the remeasurement of previous assets held by subsidiaries, the costs of closing businesses and business locations, gains and losses on the sale of businesses, cost arising from operational restructuring and the integration of acquired businesses, costs related to the termination of employment relationships as well as fines and corresponding compensation payments. Pihlajalinna has also presented costs according to the IFRS Interpretations Committee's Agenda Decision concerning cloud computing arrangements, and reversals of amortisation, as adjustment items. Cloud computing arrangements costs and reversals of amortisation according to the IFRS Interpretations Committee's Agenda Decision has not been presented as adjustment items since 1 Jan 2024.
EBITDA adjustments in the quarter amounted to EUR 0.0 (0.2) million and EUR 0.3 (-1.4) million in the financial year. Adjustments to operating profit in the quarter amounted to EUR 0.0 (0.2) million and EUR 0.3 (-1.4) million in the financial year.
2) Assets acquired via leases are regarded as equal to assets acquired by the Group itself, meaning that right-of-use assets pursuant to IFRS 16 are included in gross investments.
In 2024, Pihlajalinna will focus on organic growth and improving its profitability and financial position.
The Group expects the demand to remain steady.
Slowed economic growth and weakened consumer confidence may affect Pihlajalinna's service demand and financial result.
In 2024, Pihlajalinna will focus on organic growth and improving its profitability and financial position.
Slowed economic growth and weakened consumer confidence may affect Pihlajalinna's service demand and financial result more than expected. Price increases are expected to compensate the effects of cost inflation.
We have continued our determined efforts to strengthen organic growth and profitability. The work is progressing as planned, and the impacts of the measures have been in line with our objectives. The Group's adjusted EBITA increased to EUR 11.4 (7.3) million in the review period. Contract changes in outsourcing operations decreased Group's revenue as expected. Pihlajalinna's comparable organic revenue growth was 6.5 per cent.
The Private Healthcare Services segment revenue amounted to EUR 112.3 (105.9) million in the second quarter. The segment's comparable organic revenue growth was 9.5 per cent. Demand for services has remained stable, but as expected, seasonal fluctuations in June impacted the segment's profitability. Adjusted EBITA increased to EUR 6.2 (5.7) million. Profitability improved positively in occupational healthcare, and cooperation with insurance companies continued strong.
The Public Services segment revenue declined to EUR 66.1 (81.9) million in the second quarter due to contract changes in outsourcing operations. We continued to adapt our operations to the needs of the wellbeing services counties and focused on service development. The segment's adjusted EBITA increased to EUR 5.2 (1.6) million.
Pihlajalinna' s financial position has strengthened as planned. In June, we signed a new unsecured EUR 170 million sustainability-linked loan facilities agreement with two our partner banks. The terms and financing costs of the new agreement are in line with our anticipation.
Our long-term work to develop leadership, employee well-being, and customer satisfaction continues. The sickness absence rate decreased to 4.9 (5.8) per cent. The customer satisfaction developed strongly. The NPS for Private Healthcare Services was 85.3 (78.2) and the NPS for Public Services was 78.8 (73.5). Customer satisfaction in our surgical operations was 95.4 (93.3).
Due to the changes in Pihlajalinna's Public Services, personnel will be transferred in an orderly manner to the employment of the wellbeing services counties. At the end of June, the number of Pihlajalinna professionals was 6,721 (7,479). The decrease is mainly due to the services of Jämsän Terveys being gradually transferred to the wellbeing services county. The number of practitioners remained stable and was 2,124 (2,121).
In 2023 started determined measures to improve the profitability of Pihlajalinna will continue with the entire organisation. We also promote the development of leadership by strengthening leadership work and performance management, as well as ensuring employee well-being. Our competent and well-being professionals ensure impactful services for our customers every day. Thank you to all Pihlajalinna professionals for your decisive work in developing our operations and for your meaningful work to ensure our customers well-being every day.
An agreement was reached in June in the collective agreement negotiations for the private healthcare service sector. The outcome of the negotiations is that wages in the private healthcare service sector will be subject to a general increase of 2.4 per cent in September and pay scales will be increased by 0.51 per cent. Employees will be paid a one-off compensation payment of EUR 500 in December. The amount and timing of general increases and pay scale increases in 2025 will be determined by the wage increases in the benchmark sectors.
The Finnish Government's measures to improve the operating environment and cooperation in public and private healthcare are moving forward.
In accordance with the Government's decision, night-time emergency care services in primary care will be reduced, as will specialised care services in certain public hospitals. The public hospitals and emergency care services' changes are expected to bring savings of EUR 26.3 million for the wellbeing services counties from 2026 onwards.
According to a report published in April 2024 by the Finnish Institute for Health and Welfare, over 162,000 patients were waiting for access to non-urgent specialised care at public hospitals. The number of patients who have waited for treatment for more than six months has increased by 6,000 year-on-year.
Although private operators already bear a significant responsibility for promoting and maintaining health in Finland, their capacity to reduce treatment queues could be utilised more. The private sector produces more than half of all appointments with physicians. Nearly two million Finns are covered by occupational healthcare services, and occupational healthcare expenses account for approximately four per cent of healthcare expenses. Approximately 1.3 million Finns have private medical expenses insurance.
In June, the European Central Bank lowered its benchmark interest rates for the first time since September 2019. In addition to the effect on interest expenses, the reduction in the benchmark rates is expected to have an impact on private consumption. However, unemployment is still higher than it was a year ago. Additionally, the global security environment keeps the economic outlook uncertain.
In June, the Finnish Parliament approved legislation that will increase the value-added tax rate from 24 per cent to 25.5 per cent. The tax rate increase will enter into effect as planned on 1 September 2024, and it will increase costs in the healthcare sector.
| 4–6/2024 3 months |
4–6/2023 3 months |
change EUR |
1–6/2024 6 months |
1–6/2023 6 months |
change EUR |
2023 | |
|---|---|---|---|---|---|---|---|
| Revenue, EUR million | 174.8 | 183.6 | -8.8 | 358.0 | 371.4 | -13.4 | 720.0 |
| Revenue from divested services | 0.0 | 0.0 | 0.0 | 0.0 | 4.8 | -4.8 | 4.8 |
| Revenue from complete and partial outsourcing agreements | 49.3 | 67.9 | -18.6 | 105.1 | 134.6 | -29.5 | 259.4 |
| Adjusted EBITA, EUR million | 11.4 | 7.3 | 4.1 | 26.3 | 18.3 | 8.0 | 37.8 |
| Operating profit (EBIT), EUR million | 9.5 | 4.9 | 4.6 | 22.2 | 15.4 | 6.8 | 20.6 |
| Profit before tax (EBT), EUR million | 6.7 | 2.4 | 4.3 | 16.9 | 9.9 | 7.0 | 8.2 |
| Income tax, EUR million | -1.2 | -0.6 | -0.6 | -3.5 | -2.2 | -1.3 | -3.6 |
| Profit for the period, EUR million | 5.5 | 1.8 | 3.7 | 13.4 | 7.7 | 5.7 | 4.6 |
| Earnings per share (EPS), EUR | 0.19 | 0.07 | 0.13 | 0.49 | 0.31 | 0.18 | 0.19 |
Pihlajalinna's revenue was EUR 174.8 (183.6) million, a decrease of EUR -8.8 million, or -4.8 per cent. In Public Services, the termination of cost liability for demanding specialised care, the gradual transfer of the services agreement of Jämsän Terveys and other changes to outsourcing agreements decreased revenue by EUR 19.3 million. Pihlajalinna's comparable organic revenue1) growth was EUR 10.7 million, or 6.5 per cent.
Adjusted operating profit before the amortisation and impairment of intangible assets (EBITA) was EUR 11.4 (7.3) million. The adjusted EBITA margin was 6.5 (4.0) per cent. Adjustments to EBIT amounted to EUR 0.0 (0.2) million. In Public Services, profitability was improved by efficiency improvement measures and in Private Healthcare Services, profitability was improved by commercial measures and enhanced service processes, particularly in occupational healthcare services.
Pihlajalinna's EBIT was EUR 9.5 (4.9) million, an increase of EUR 4.6 million.
The Group's net financial expenses amounted to EUR -2.8 (-2.5) million. Refinancing measures in June generated a total of EUR 0.6 million in non-recurring financial expenses recognised through profit or loss. Profit before taxes was EUR 6.7 (2.4) million. Taxes in the income statement was EUR -1.2 (-0.6) million.
Profit was EUR 5.5 (1.8) million. Earnings per share (EPS) was EUR 0.19 (0.07).
Pihlajalinna's revenue was EUR 358.0 (371.4) million, a decrease of EUR -13.4 million, or -3.6 per cent. In Private Healthcare Services, the divestment of dental care services decreased revenue by EUR 4.8 million and in Public Services, the termination of cost liability for demanding specialised care, the gradual transfer of the services agreement of Jämsän Terveys and other changes to outsourcing agreements decreased revenue by EUR 32.3 million. Pihlajalinna's comparable organic revenue1) growth was EUR 24.1 million, or 7.2 per cent.
Adjusted operating profit before the amortisation and impairment of intangible assets (EBITA) was EUR 26.3 (18.3) million, an increase of EUR 8.0 million, or 43.6 per cent. The adjusted EBITA margin was 7.3 (4.9) per cent. Adjustments to EBIT amounted to EUR 0.3 (-1.4) million. In Public Services, profitability was improved by efficiency improvement measures and in Private Healthcare Services, profitability was improved by commercial measures, enhanced service processes and cost control.
Pihlajalinna's EBIT was EUR 22.2 (15.4) million, an increase of EUR 6.8 million.
The Group's net financial expenses amounted to EUR -5.3 (-5.5) million. Refinancing measures in June generated a total of EUR 0.6 million in non-recurring financial expenses recognised through profit or loss. Profit before taxes was EUR 16.9 (9.9) million. Taxes in the income statement was EUR -3.5 (-2.2) million.
Profit was EUR 13.4 (7.7) million. Earnings per share (EPS) was EUR 0.49 (0.31).
| 4–6/2024 3 months |
4–6/2023 3 months |
change | 1–6/2024 6 months |
1–6/2023 6 months |
change | 2023 | |
|---|---|---|---|---|---|---|---|
| Cash flow from operating activities, EUR million | 27.5 | 27.3 | 0.2 | 58.7 | 46.3 | 12.4 | 79.0 |
| of which change in working capital, EUR million | 4.8 | 10.1 | -5.3 | 9.0 | 7.7 | 1.3 | 0.0 |
| Net cash flow from investing activities, EUR million | -6.0 | -5.1 | -0.9 | -8.7 | -10.9 | 2.2 | -18.5 |
| Net cash flow from financing activities, EUR million | -35.3 | -11.2 | -24.1 | -61.5 | -22.4 | -39.2 | -49.2 |
| Cash at end of period, EUR million | 13.0 | 26.1 | -13.1 | 24.5 | |||
| Gearing, % | 211.0 | 236.4 | -25.5 | 243.9 | |||
| Gearing, excluding IFRS 16, % | 75.8 | 95.7 | -19.8 | 94.38 | |||
| Interest-bearing net debt, EUR million | 325.1 | 354.1 | -29.0 | 352.7 | |||
| Interest-bearing net debt excluding IFRS 16, EUR million | 122.1 | 147.9 | -25.8 | 142.0 |
Pihlajalinna Group's total statement of financial position was EUR 633.6 (677.0) million. Consolidated cash and cash equivalents was EUR 13.0 (26.1) million.
Net cash flow from operating activities during the review period was EUR 58.7 (46.3) million. The change in net working capital was EUR 9.0 (7.7) million.
Net cash flow from investing activities was EUR -8.7 (-10.9) million in the review period. Investments in tangible and intangible assets was EUR -7.1 (-15.1) million. In the comparison period, the divestment of the Group's dental care services improved net cash flow from investing activities by EUR 5.7 million. The Group's cash flow after investments (free cash flow) was EUR 50.0 (35.4) million.
Net cash flow from financing activities was EUR -61.5 (-22.4) million in the review period. The change in financial liabilities, including changes in credit limits, was EUR -31.4 (-22.9) million. During the review period, Pihlajalinna amortised its long-term loan by a total of EUR 30.0 million. In the comparison period, Pihlajalinna issued EUR 20 million hybrid bond. During the review period, Pihlajalinna paid hybrid bond interest EUR 2.4 (0.0) million which has been recorded as a deduction from retained earnings, net of tax. Interest paid and other financial expenses was EUR -8.6 (-2.1) million. During the first quarter of 2023, the Group sold its interest rate swap agreement. The sale had an effect of approximately EUR 3.9 million on the net cash flow of interest paid and other financial expenses. At the end of the review period, due to refinancing, Pihlajalinna paid the accrued interest and expenses on its long-term loan as well as non-recurring refinancing costs.
Gross investments amounted to EUR 23.0 (36.4) million. The Group's gross investments which consisted of development, additional and replacement investments, amounted to EUR 8.5 (19.4) million. Gross investments in right-of-use assets amounted to EUR 11.5 (17.0) million. Gross investments in M&A transactions amounted to EUR 3.0 (0.7) million. On 1 May 2024, Pihlajalinna acquired full ownership of its former associated company Kuura Digilääkäri Oy. The Group's previous holding in the company was 45 per cent.
Investment commitments for the Group's development, additional and replacement investments amounted to approximately EUR 1.6 (2.2) million. The investment commitments are related to business premises changes, additional and replacement investments in clinical equipment and information system projects.
The digital projects implemented during the review period did not meet the definition of an intangible asset according to IFRS standards regarding the company's own work. According to management's assessment, the economic benefit of own work realises over a short term. In the comparison period, there were a total of 1.2 million euros of capitalizations of the company's own work that met the criteria.
Pihlajalinna changed its segment reporting effective from 1 January 2024. Pihlajalinna has two reportable segments: Private Healthcare Services and Public Services. The new reporting structure follows Pihlajalinna's business model and organisational structure.
Operating segment consists of private clinic, diagnostics, hospital, occupational healthcare, remote and fitness center services. These comprehensive care path services are provided by Pihlajalinna to corporate customers, insurance companies, the public sector and private customers through its nationwide network of medical centers and diverse digital channels.
| 4–6/2024 | 4–6/2023 | change | 1–6/2024 | 1–6/2023 | change | ||
|---|---|---|---|---|---|---|---|
| 3 months | 3 months | EUR | 6 months | 6 months | EUR | 2023 | |
| Segment revenue, EUR million | 112.3 | 105.9 | 6.4 | 226.9 | 218.5 | 8.4 | 423.1 |
| Operating profit (EBIT), EUR million | 4.5 | 3.5 | 1.0 | 13.0 | 10.8 | 2.2 | 19.4 |
| Operating profit (EBIT), % | 4.0 | 3.3 | 5.7 | 4.9 | 4.6 | ||
| EBITA, EUR million | 6.2 | 5.3 | 0.9 | 16.6 | 14.4 | 2.2 | 26.7 |
| EBITA, % | 5.5 | 5.0 | 7.3 | 6.6 | 6.3 | ||
| Adjusted EBITA, EUR million | 6.2 | 5.7 | 0.5 | 16.9 | 13.8 | 3.0 | 27.2 |
| Adjusted EBITA, % | 5.5 | 5.4 | 7.4 | 6.3 | 6.4 |
Revenue from Private Healthcare Services was EUR 112.3 (105.9) million, an increase of EUR 6.4 million, or 6.1 per cent. Comparable organic revenue growth1) in Private Healthcare Services segment was EUR 9.8 million, or 9.5 per cent. The appointment volumes of Pihlajalinna's private clinics were on a par with the comparison period.
Adjusted EBITA was EUR 6.2 (5.7) million, an increase of EUR 0.5 million, or 8.6 per cent. The adjusted EBITA margin was 5.5 (5.4) per cent. Profitability improved particularly in occupational healthcare services and clinic operations due to price increases, the improved efficiency of service processes and cost control. Conversion, which is the ratio of diagnostics revenue to revenue from appointments, was on a par with the comparison period. Adjustments totalled EUR 0.0 (0.4) million.
Operating profit (EBIT) was EUR 4.5 (3.5) million, an increase of EUR 1.0 million.
Revenue from Private Healthcare Services was EUR 226.9 (218.5) million, an increase of EUR 8.4 million, or 3.8 per cent. The divestment of dental care services decreased revenue by EUR 4.8 million. Comparable organic revenue growth1) in Private Healthcare Services segment was EUR 19.3 million, or 9.3 per cent. The appointment volumes of Pihlajalinna's private clinics decreased slightly year-on-year.
Adjusted EBITA was EUR 16.6 (14.4) million, an increase of EUR 2.2 million, or 15.6 per cent. The adjusted EBITA margin was 7.4 (6.3) per cent. Profitability improved particularly in occupational healthcare services and clinic operations due to price increases, the improved efficiency of service processes and cost control. Conversion, which is the ratio of diagnostics revenue to revenue from appointments, was on a par with the comparison period. Adjustments totalled EUR 0.3 (-0.5) million.
Operating profit (EBIT) was EUR 13.0 (10.8) million, an increase of EUR 2.2 million. In the comparison period, EBIT was increased by a sales gain of EUR 3.6 million recognised on the divestment of dental care services.
Operating segment consists of social and healthcare services produced primarily for the public sector, which include outsourcing and housing services, mainly remotely produced responsible doctor services, as well as a wide range of staffing and recruitment services.
| 4–6/2024 | 4–6/2023 | change | 1–6/2024 | 1–6/2023 | change | ||
|---|---|---|---|---|---|---|---|
| 3 months | 3 months | EUR | 6 months | 6 months | EUR | 2023 | |
| Segment revenue, EUR million | 66.1 | 81.9 | -15.8 | 138.8 | 161.7 | -22.9 | 314.3 |
| Operating profit (EBIT), EUR million | 5.1 | 1.5 | 3.6 | 9.2 | 4.6 | 4.6 | 1.2 |
| Operating profit (EBIT), % | 7.7 | 1.8 | 6.6 | 2.9 | 0.4 | ||
| EBITA, EUR million | 5.2 | 1.7 | 3.5 | 9.4 | 5.1 | 4.3 | 2.1 |
| EBITA, % | 7.8 | 2.1 | 6.8 | 3.1 | 0.7 | ||
| Adjusted EBITA, EUR million | 5.2 | 1.6 | 3.6 | 9.4 | 4.5 | 5.0 | 10.6 |
| Adjusted EBITA, % | 7.9 | 1.9 | 6.8 | 2.8 | 3.4 |
Revenue from Public Services was EUR 66.1 (81.9) million, a decrease of EUR 15.8 million, or 19.3 per cent. The termination of cost liability for demanding specialised care, the gradual transfer of the services agreement of Jämsän Terveys and other changes to outsourcing agreements decreased revenue by EUR 19.3 million. Comparable organic revenue growth1) in Public Services was EUR 0.4 million, or 0.5 per cent.
Adjusted EBITA was EUR 5.2 (1.7) million, an increase of EUR 3.5 million. The adjusted EBITA margin was 7.9 (1.9) per cent. Profitability was improved by efficiency improvement measures and contract changes in complete outsourcing. Adjustments totalled EUR 0.0 (-0.1) million.
EBIT amounted to EUR 5.1 (1.5) million, an increase of EUR 3.6 million.
Revenue from Public Services was EUR 138.8 (161.7) million, a decrease of EUR 22.9 million, or 14.2 per cent. The termination of cost liability for demanding specialised care, the gradual transfer of the services agreement of Jämsän Terveys and other changes to outsourcing agreements decreased revenue by EUR 32.3 million. Comparable organic revenue growth1) in Public Services was EUR 3.7 million, or 2.8 per cent.
Adjusted EBITA was EUR 9.4 (5.1) million, an increase of EUR 4.3 million, or 85.6 per cent. The adjusted EBITA margin was 6.8 (2.8) per cent. Profitability was improved by efficiency improvement measures and contract changes in complete outsourcing. Adjustments totalled EUR 0.0 (-0.6) million.
EBIT amounted to EUR 9.2 (4.6) million, an increase of EUR 4.6 million.
¹) The following items have been excluded from the comparison period revenue: the divestment of dental care services, the transfer of cost liability for demanding specialised care, the gradual termination of Jämsän Terveys' service agreement, other changes to outsourcing agreements and COVID-19 services.
At the end of the review period, the number of personnel amounted to 6,721 (7,479), a decrease of -758 persons or -10 per cent. The Group's personnel as full-time equivalents was 4,753 (4,978), a decrease of - 224 persons or -5 per cent. As a result of the gradual transfer of the Jämsän Terveys service agreement, the number of the Group's employees decreased by approximately 400 from the end of 2023. Converted to full-time equivalents, the decrease in the number of employees was approximately 150.
At the end of the review period, the Public Services had 3,688 (4,324) employees and the Private Healthcare Services 3,033 (3,155) employees. Converted into full-time equivalents, the Public Services had 2,728 (2,960) employees and the Private Healthcare Services 2,026 (2,018) employees.
Kuusiolinna Terveys commenced change negotiations in January 2024 to align its operations to the needs of the wellbeing services county. The negotiations were concluded in April. The outcome of the negotiations included operational changes to the network of clinics, the downscaling of operations, terminations of employment contracts and switching some of the personnel to part-time employment.
The Group employee benefit expenses totalled EUR 164.6 (165.7) million, a decrease of EUR -1.1 million. A non-recurring cost item of EUR 0.8 million related to the collective agreement for the private social services sector (SOSTES) was paid during the review period and recognised as an expense in the review period.
In the review period, sickness-related absences rate amongst the personnel was 4.9 (5.8) per cent.
At the end of the review period, the number of practitioners was 2 124 (2 121).
Pihlajalinna rearranged its long-term debt financing with a sustainability-linked financing arrangement in June 2024. The agreement includes a EUR 110 million term loan for refinancing the Group's previous debt, and a revolving credit facility of EUR 60 million for general financing purposes. The financing agreement is for three years and includes two option years.
The financing arrangement includes the customary financial covenants equivalent to the previous arrangement, concerning leverage (ratio of net debt to pro forma EBITDA) and gearing. IFRS 16 lease liabilities are not considered in the calculation of the covenants (Frozen GAAP). The loan margin of the financing is additionally linked to Pihlajalinna' s main sustainability targets: patient satisfaction, access to surgical treatment and employee engagement. Sustainability objectives have a minor effect on the loan margin, depending on how many of the agreed-upon sustainability targets are achieved.
The original gearing covenant of the financing arrangement is 115 per cent and the leverage covenant is 3.75. At the end of the review period, gearing in accordance with the financing arrangement was 75.8 per cent and leverage stood at 2.37.
Pihlajalinna issued EUR 20 million hybrid bond on 27 March 2023. The hybrid bond bears a fixed interest rate of 12.00 percent per annum until 27 March 2026 ("Reset Date"), and from the Reset Date, a floating interest rate as defined in the terms and conditions of the capital securities.
The Group has credit limit agreements valid until further notice, totalling EUR 10 million. The notice period of the credit limit agreements is one month. At the end of the review period, Pihlajalinna had EUR 70 million in unused committed credit limits. Unused credit limits consist of EUR 10 million credit limit agreement and EUR 60 million unused revolving credit facility.
The company has an interest rate swap agreement with a nominal value of EUR 65 million, which is used to convert the floating interest rate of the financing arrangement to fixed interest rate. Cash flow hedge accounting is applied to the interest rate swap agreement, which means that the effective portion of the change in fair value is recognised in other comprehensive income. The start date of the interest rate swap was in March 2023, and it is valid until 25 March 2027.
The Management Team includes CEO Tuomas Hyyryläinen, Chief Strategy and Group Operations Officer (CSOO) Heikki Färkkilä, interim COO Public Services Seppo Kariniemi, Chief Communications and Sustainability Officer Tuula Lehto, CIO Lauri Muhonen (from 1 August 2024), CFO Tarja Rantala, CMO Sari Riihijärvi, and CLO Marko Savolainen.
On 27 May 2024, Pihlajalinna issued a release regarding an appointment to strengthen the company's Management Team. Anu Kallio was appointed as COO, Private Healthcare Services, and a member of the Group Management Team. She will join Pihlajalinna from Humana Finland, where she has been working as Managing Director since 2020. Kallio will start in the position on 1 December 2024 at the latest.
The Annual General Meeting on 10 April 2024 resolved that the number of the members of the Board of Directors shall be fixed at seven members instead of the previous eight. Kim Ignatius, Heli Iisakka, Hannu Juvonen, Tiina Kurki, Jukka Leinonen, Leena Niemistö and Mikko Wirén were re-elected to serve as members of the Board of Directors until the next Annual General Meeting.
The Annual General Meeting elected Jukka Leinonen as the Chair of the Board and Leena Niemistö as the Vice-Chair of the Board.
In accordance with the proposal of the Board of Directors, the AGM decided that a dividend of EUR 0.07 per share be distributed for the financial year that ended on 31 December 2023 based on the adopted statement of financial position. The dividend was paid on 19 April 2024.
The Annual General Meeting on 10 April 2024 authorised the Board of Directors to decide on the acquisition of a maximum of 2,260,000 shares, which is approximately 10 per cent of the company's current share capital. Own shares may be repurchased based on the authorisation only by using unrestricted equity. Targeted share acquisition is possible. The authorisation is effective until the next Annual General Meeting, or until 30 June 2025 at the latest.
The Annual General Meeting also authorised the Board of Directors to decide on a share issue and other special rights conferring an entitlement to shares under Chapter 10, Section 1 of the Limited Liability Companies Act. The number of shares issued pursuant to the authorisation may not exceed 2,260,000 shares, which corresponds to approximately 10 per cent of all existing shares in the company. The authorisation concerns both the issuance of new shares and the sale or transfer of the company's own shares. The authorisation permits a targeted share issue. The authorisation is effective until the next Annual General Meeting, or until 30 June 2025 at the latest.
Pihlajalinna conveyed a total of 10,000 own shares to CEO Tuomas Hyyryläinen in January. The remuneration was related to the right agreed upon for the CEO to acquire shares at the beginning of the share-based incentive scheme, when Pihlajalinna conveyed shares in exchange for purchases.
In May, Pihlajalinna conveyed a total of 11,977 own shares to the members of Pihlajalinna's Board of Directors as part of the Board of Directors' annual remuneration.
Pihlajalinna started repurchasing the company's own shares on 27 March 2024 and completed the repurchase on 28 June 2024. The shares were repurchased for use as part of the payment of remuneration under the Group's share-based incentive programme and the annual remuneration of the members of the Board of Directors. During the aforementioned period, Pihlajalinna acquired a total of 109,181 of its own shares for an average price of EUR 8.5795 per share.
Following the repurchase of shares and the transfers of shares mentioned above, Pihlajalinna held 141,184 of its own shares at the end of the review period, corresponding to approximately 0.62 per cent of the total number of shares and votes.
The total number of shares was 22,620,135 of which 22,478,951 were outstanding and 141,184 were held by the company which corresponds to 0.62 per cent of all shares and votes. At the end of the review period, the company had 14,732 (15,451) shareholders.
The trading code for the shares on the Nasdaq Helsinki main market is PIHLIS. Pihlajalinna Plc has been classified as a Mid Cap company in the Healthcare sector.
| Share-related information, outstanding shares | 4–6/2024 | 4–6/2023 | 1–6/2024 | 1–6/2023 | 2023 |
|---|---|---|---|---|---|
| No. of shares outstanding at end of period | 22,478,951 | 22,561,505 | 22,478,951 | 22,561,505 | 22,566,155 |
| Average no. of shares outstanding during period | 22,514,876 | 22,556,552 | 22,544,940 | 22,553,163 | 22,557,957 |
| Highest price, EUR | 9.74 | 9.90 | 9.74 | 9.90 | 9.90 |
| Lowest price, EUR | 7.62 | 7.48 | 6.88 | 6.82 | 6.82 |
| Average price, EUR ¹⁾ | 8.00 | 9.00 | 7.56 | 8.66 | 8.20 |
| Closing price, EUR | 9.34 | 9.39 | 9.34 | 9.39 | 7.06 |
| Share turnover, 1,000 shares | 815 | 748 | 2,291 | 1,727 | 2,801 |
| Share turnover, % | 3.6 | 3.3 | 10.2 | 7.7 | 12.4 |
| Market capitalisation at end of period, EUR million |
210.0 | 211.9 | 210.0 | 211.9 | 159.3 |
¹⁾ average rate weighted by trading level
Pihlajalinna's operations are affected by strategic risks, operational, financial and damage risks. In its risk management, Pihlajalinna's aim is to operate as systematically as possible and incorporate risk management in normal business processes. The Group invests in quality management systems and the management of occupational safety and work ability risks. Pihlajalinna aims to limit the potential adverse impacts of risks. The assessment of sustainability-related risks plays an important role in risk management.
Pihlajalinna operates only in Finland. Uncertainties in world politics, such as the Russia's invasion of Ukraine and situation in the Middle East has indirect impacts on the Group's operations due to the slowing of economic growth, supply chain disruptions, high inflation, and changing market interest rates. Pihlajalinna will refrain from all business activities with parties subject to economic sanctions.
In all its operations, Pihlajalinna considers data protection, information security and related requirements. Information security and jeopardised data protection can lead to significant reputational damage and claims for compensation, among other consequences. Pihlajalinna has taken steps to prepare for the elevated risk of cyber-attacks related to the war in Ukraine and Finland's NATO membership.
High sickness-related absences among the personnel may reduce the company's profitability and complicates service provision. The company has also identified uncertainties related to the availability of personnel in the social and healthcare sector and development of wages. The costs of wage harmonisation in the social and healthcare sector in relation to the creation of the wellbeing services counties also remain uncertain to some degree.
Pihlajalinna has recognised risks associated with projects related to the company's growth, including acquisitions, digital development, and information system projects. The successful implementation of these projects is a precondition for profitable growth in accordance with the company's strategy.
Monitoring and forecasting the covenants of the company's financing agreements is a significant part of the company's risk management. The company's financing agreement and the hybrid bond issued on 27 March 2023 are described in more detail in the section Financing arrangements.
General cost inflation and wage inflation have a negative impact on the cost level and, consequently, on Pihlajalinna's business operations and profitability. In addition, inflation and high interest rates affect consumers' disposable income and employment trends, which in turn have an impact on the demand for private healthcare services.
The most significant risks and uncertainties in social and healthcare services are linked to the policies and legislation implemented in Finnish society.
A company belonging to the Pihlajalinna Group is currently the subject of a tax audit pertaining to a remuneration scheme what was in place.
Jämsän Terveys's agreement with the wellbeing services county of Central Finland will expire in August 2025. The cost liability for demanding specialised care specified in the agreement ended on 1 July 2023. It has been agreed with the wellbeing services county of Central Finland that the services will gradually be
transferred to the wellbeing services county in the first half of 2024. These changes will decrease Jämsän Terveys's revenue approximately by 31 million euros from 2023 levels.
The primary and specialised care services provided by Jokilaakson Terveys will continue at Jokilaakso Hospital in accordance with the subcontracting agreement until 2025. Jokilaakson Terveys has an exception permit issued by the Ministry of Social Affairs and Health for round-the-clock emergency and on-call services in primary healthcare, as required for its operations. The permit is currently valid until the end of 2024, but the wellbeing services county of Central Finland has applied in January 2024 an extension of the permit until the end of 2025.
30 October 2023, the regional council of the South Ostrobothnia wellbeing services county decided to terminate the outsourcing agreement with Kuusiolinna Terveys, which was originally valid until 2030, with the termination set for the end of 2025. Kuusiolinna Terveys and Pihlajalinna Terveys appealed the decision, and an appeal regarding the matter was lodged with the Supreme Administrative Court. The parties subsequently negotiated on separating demanding specialised care from Kuusiolinna Terveys' service agreement. The negotiations led to a settlement on the conditions for separating demanding specialised care, and an agreement on the matter was signed on 30 April 2024. In accordance with the terms of the agreement, Kuusiolinna Terveys and Pihlajalinna Terveys have withdrawn their appeals concerning the decision made by the wellbeing services county of South Ostrobothnia on 30 October 2023. This change is estimated to decrease Kuusiolinna Terveys' revenue by approximately EUR 30 million euros from 2023 levels.
Pihlajalinna is involved in certain pending legal proceedings concerning employment relationships, but they are not expected to have a significant financial impact on the Group.
The company's subsidiary Jämsän Terveys Oy has taken legal action in the district court against the City of Jämsä, a former client, mainly concerning COVID-19-related costs which the City of Jämsä has not paid in breach of the service agreement. In addition, a difference of opinion has emerged between the company and the city during the 2022 financial year on the impact of the transfer of personnel on the annual fee under the service agreement.
On 22 November 2023, the Vaasa Court of Appeal handed down its ruling on the dispute concerning the service agreement between Jämsän Terveys Oy and the City of Jämsä. The Court of Appeal decided to uphold the decision of the District Court. Pihlajalinna has submitted an application for leave to appeal to the Supreme Court and an appeal concerning part of the judgment of the Vaasa Court of Appeal.
On 17 July 2024, Pihlajalinna announced that it was raising its profitability guidance for 2024 and provided preliminary information on revenue and profitability for the second quarter of 2024. The Group expects the adjusted operating profit before the amortisation and impairment of intangible assets (EBITA) for 2024 to exceed EUR 48 million (EUR 37.8 million in 2023). The Group expects demand to remain stable. The revenue outlook remained unchanged.
More information is available in the stock exchange release on Pihlajalinna's website.
Interim Report January–September: Thursday, 7 November 2024
Helsinki, 8 August 2024
The Board of Directors of Pihlajalinna Plc
| EUR million | Note | 4–6/2024 | 4–6/2023 | 1–6/2024 | 1–6/2023 | 2023 |
|---|---|---|---|---|---|---|
| Revenue | 2 | 174.8 | 183.6 | 358.0 | 371.4 | 720.0 |
| Other operating income | 0.9 | 2.1 | 1.9 | 6.9 | 7.5 | |
| Materials and services | 3 | -50.6 | -66.4 | -103.5 | -133.3 | -255.2 |
| Employee benefit expenses | 4 | -81.4 | -82.8 | -164.6 | -165.7 | -322.8 |
| Other operating expenses | 5 | -21.0 | -18.8 | -43.4 | -38.5 | -76.6 |
| Share of profit in associated companies and joint ventures |
0.0 | 0.0 | 0.0 | 0.0 | -0.5 | |
| EBITDA | 22.7 | 17.7 | 48.3 | 40.8 | 72.5 | |
| Depreciation, amortisation and impairment | 6 | -13.1 | -12.8 | -26.1 | -25.3 | -51.9 |
| Operating profit (EBIT) | 9.5 | 4.9 | 22.2 | 15.4 | 20.6 | |
| Financial income | 0.4 | 0.2 | 0.6 | 0.3 | 0.4 | |
| Financial expenses | 7 | -3.2 | -2.7 | -5.9 | -5.8 | -12.7 |
| Profit before taxes | 6.7 | 2.4 | 16.9 | 9.9 | 8.2 | |
| Income tax | 8 | -1.2 | -0.6 | -3.5 | -2.2 | -3.6 |
| Profit for the period | 5.5 | 1.8 | 13.4 | 7.7 | 4.6 | |
| Attributable to: | ||||||
| To the owners of the parent company | 4.8 | 2.0 | 12.0 | 7.4 | 5.7 | |
| To non-controlling interests | 0.7 | -0.2 | 1.4 | 0.3 | -1.1 | |
| Earnings per share calculated based on the result for the period attributable to the owners of the parent company (EUR) |
||||||
| Basic | 0.19 | 0.07 | 0.49 | 0.31 | 0.19 | |
| Diluted | 0.19 | 0.07 | 0.49 | 0.31 | 0.19 |
| EUR million | Note | 4–6/2024 | 4–6/2023 | 1–6/2024 | 1–6/2023 | 2023 |
|---|---|---|---|---|---|---|
| Profit for the period | 5.5 | 1.8 | 13.4 | 7.7 | 4.6 | |
| Other comprehensive income that will be reclassified subsequently to profit or loss |
||||||
| Cash flow hedge | ||||||
| Recorded in equity | 0.4 | 0.6 | 0.4 | 0.1 | -1.0 | |
| Transferred to income statement | -0.2 | -0.3 | -0.5 | -0.3 | -0.7 | |
| Income tax on other comprehensive income | 0.0 | -0.1 | 0.0 | 0.0 | 0.4 | |
| Other comprehensive income for the reporting period | 0.1 | 0.3 | -0.1 | -0.1 | -1.4 | |
| Total comprehensive income for the reporting period | 5.7 | 2.1 | 13.3 | 7.6 | 3.2 | |
| Attributable to: | ||||||
| To the owners of the parent company | 5.0 | 2.2 | 11.9 | 7.3 | 4.3 | |
| To non-controlling interests | 0.7 | -0.2 | 1.4 | 0.3 | -1.1 |
| EUR million | Note | 30 Jun 2024 | 30 Jun 2023 | 2023 |
|---|---|---|---|---|
| ASSETS | ||||
| Non-current assets | ||||
| Property, plant and equipment | 10 | 65.8 | 68.8 | 65.8 |
| Goodwill | 9 | 254.8 | 252.7 | 251.8 |
| Intangible assets | 9 | 18.5 | 22.3 | 21.1 |
| Right-of-use assets | 11 | 195.4 | 195.6 | 203.9 |
| Interests in associates | 0.0 | 2.1 | 1.6 | |
| Other investments | 0.2 | 0.8 | 0.2 | |
| Other receivables | 6.0 | 11.2 | 6.1 | |
| Deferred tax assets | 13.9 | 16.8 | 14.6 | |
| Total non-current assets | 554.4 | 570.3 | 565.0 | |
| Current assets | ||||
| Inventories | 4.5 | 4.6 | 4.5 | |
| Trade and other receivables | 16 | 61.2 | 75.3 | 61.5 |
| Current tax assets | 0.5 | 0.8 | 2.0 | |
| Cash and cash equivalents | 13.0 | 26.1 | 24.5 | |
| Total current assets | 79.1 | 106.8 | 92.5 | |
| Total assets | 633.6 | 677.0 | 657.5 | |
| EUR million | Note | 30 Jun 2024 | 30 Jun 2023 | 2023 |
| EQUITY AND LIABILITIES | ||||
| Equity attributable to owners of the parent | ||||
| Share capital | 0.1 | 0.1 | 0.1 | |
| Fair value reserve | 2.6 | 4.0 | 2.7 | |
| Reserve for invested unrestricted equity | 116.5 | 116.5 | 116.5 | |
| Hybrid bond | 14 | 20.0 | 20.0 | 20.0 |
| Retained earnings | 4.9 | 2.8 | 3.0 | |
| Profit for the period | 12.0 | 7.4 | 5.7 | |
| 156.1 | 150.8 | 148.0 | ||
| Non-controlling interests | -2.0 | -1.1 | -3.4 | |
| Total equity | 154.1 | 149.8 | 144.6 | |
| Deferred tax liabilities | 8.0 | 8.5 | 8.5 | |
| Provisions | 1.0 | 0.0 | 0.1 | |
| Lease liabilities | 12 | 191.2 | 198.0 | 199.8 |
| Financial liabilities | 15 | 114.8 | 150.5 | 144.5 |
| Other non-current liabilities | 0.6 | 0.7 | 0.7 | |
| Total non-current liabilities | 315.6 | 357.7 | 353.6 | |
| Trade and other payables | 129.2 | 134.9 | 125.3 | |
| Current tax liabilities | 2.2 | 0.7 | 0.1 | |
| Provisions | 0.1 | 0.2 | 0.1 | |
| Lease liabilities | 12 | 30.4 | 29.4 | 30.8 |
| Financial liabilities | 15 | 2.0 | 4.3 | 3.0 |
| Total current liabilities | 163.9 | 169.5 | 159.3 | |
| Total liabilities | 479.4 | 527.3 | 512.9 | |
| Total equity and liabilities | 633.6 | 677.0 | 657.5 |
| Equity attributable to owners of the parent company |
|||||||
|---|---|---|---|---|---|---|---|
| EUR million | Share capital |
Reserve for invested unrestricted equity |
Fair value reserve |
Hybrid bond |
Retained earnings |
Non-controlling interests |
Equity Total |
| Total equity, 1 Jan 2023 | 0.1 | 116.5 | 4.1 | 3.3 | -1.1 | 122.9 | |
| Profit for the period | 7.4 | 0.3 | 7.7 | ||||
| Comprehensive income for the period | -0.1 | -0.1 | |||||
| Total comprehensive income for the period |
-0.1 | 7.4 | 0.3 | 7.6 | |||
| Share-based benefits | 0.1 | 0.1 | |||||
| Total transactions with owners | 0.1 | 0.1 | |||||
| Changes in NCI without a change in control | -0.2 | -0.1 | -0.3 | ||||
| Other changes | 0.1 | -0.1 | 0.0 | ||||
| Total changes in subsidiary shareholdings | -0.1 | -0.2 | -0.3 | ||||
| Proceeds from hybrid bond | 20.0 | 20.0 | |||||
| Hybrid bond expenses | -0.4 | -0.4 | |||||
| Total equity, 30 Jun 2023 | 0.1 | 116.5 | 4.0 | 20.0 | 10.3 | -1.1 | 149.8 |
| Equity attributable to owners of the parent company |
|||||||
|---|---|---|---|---|---|---|---|
| EUR million | Share capital |
Reserve for invested unrestricted equity |
Fair value reserve |
Hybrid bond |
Retained earnings |
Non-controlling interests |
Equity Total |
| Total equity, 1 Jan 2024 | 0.1 | 116.5 | 2.7 | 20.0 | 8.8 | -3.4 | 144.6 |
| Profit for the period | 12.0 | 1.4 | 13.4 | ||||
| Comprehensive income for the period | -0.1 | -0.1 | |||||
| Total comprehensive income for the period |
-0.1 | 12.0 | 1.4 | 13.3 | |||
| Dividends paid | -1.6 | -1.6 | |||||
| Acquisition of own shares | -0.9 | -0.9 | |||||
| Share-based benefits | 0.5 | 0.5 | |||||
| Total transactions with owners | -2.0 | -2.0 | |||||
| Other changes | 0.1 | 0.1 | |||||
| Total changes in subsidiary shareholdings | 0.1 | 0.1 | |||||
| Hybrid bond interest | -1.9 | -1.9 | |||||
| Total equity, 30 Jun 2024 | 0.1 | 116.5 | 2.6 | 20.0 | 16.9 | -2.0 | 154.1 |
| 4–6/2024 | 4–6/2023 | 1–6/2024 | 1–6/2023 | ||
|---|---|---|---|---|---|
| EUR million | 3 months | 3 months | 6 months | 6 months | 2023 |
| Cash flow from operating activities | |||||
| Profit for the period | 5.5 | 1.8 | 13.4 | 7.7 | 4.6 |
| Adjustments to cash flow from operating activities: | |||||
| Taxes | 1.2 | 0.6 | 3.5 | 2.2 | 3.6 |
| Depreciation, amortisation and impairment | 13.1 | 12.8 | 26.1 | 25.3 | 51.9 |
| Financial income and expenses | 2.8 | 2.5 | 5.3 | 5.5 | 12.4 |
| Other | -0.1 | 0.0 | -0.1 | -2.7 | 6.4 |
| Net cash generated from operating activities before change in working capital |
22.6 | 17.7 | 48.2 | 38.0 | 78.9 |
| Change in working capital | 4.8 | 10.1 | 9.0 | 7.7 | 0.0 |
| Interest received | 0.5 | 0.1 | 0.5 | 0.2 | 0.4 |
| Taxes paid | -0.3 | -0.5 | 0.9 | 0.4 | -0.4 |
| Net cash flow from operating activities | 27.5 | 27.3 | 58.7 | 46.3 | 79.0 |
| Cash flow from investing activities | |||||
| Investments in tangible and intangible assets | -4.1 | -3.6 | -7.1 | -15.1 | -22.9 |
| Proceeds from disposal of property, | |||||
| plant and equipment and intangible assets and prepayments | 0.3 | 0.0 | 0.7 | 0.1 | 0.3 |
| Changes in other receivables and investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Sale of subsidiaries with time-of-sale liquid assets deducted | 7.7 | 7.7 | |||
| Granted loans | -2.1 | -2.1 | |||
| Dividends received | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Acquisition of subsidiaries less cash and cash equivalents at date of acquisition |
-2.2 | -1.5 | -2.2 | -1.5 | -1.5 |
| Net cash flow from investing activities | -6.0 | -5.1 | -8.7 | -10.9 | -18.5 |
| Cash flow from financing activities | |||||
| Changes in non-controlling interests | -0.3 | ||||
| Acquisition of own shares | -0.9 | -0.9 | |||
| Proceeds from and repayment of borrowings | -20.7 | -0.4 | -31.4 | -22.9 | -29.0 |
| Repayment of lease liabilities | -8.1 | -8.0 | -16.1 | -15.8 | -31.8 |
| Interest and other operational financial expenses | -4.1 | -2.9 | -8.6 | -2.1 | -6.2 |
| Dividends paid and other profit distribution | -1.6 | 0.0 | -2.2 | -1.2 | -1.5 |
| Proceeds from hybrid bond | 20.0 | 20.0 | |||
| Hybrid bond interests and expenses | -2.4 | -0.4 | -0.4 | ||
| Net cash flow from financing activities | -35.3 | -11.2 | -61.5 | -22.4 | -49.2 |
| Changes in cash and cash equivalents | -13.8 | 11.0 | -11.5 | 13.0 | 11.4 |
| Cash at beginning of period | 26.8 | 15.1 | 24.5 | 13.1 | 13.1 |
| Cash at end of period | 13.0 | 26.1 | 13.0 | 26.1 | 24.5 |
This Half Year Financial Report has been prepared in compliance with the IFRS standards currently in effect, and its preparation has followed the requirements of IAS 34 (Interim Financial Reporting).
The Half Year Financial Report applies the accounting policies presented in the consolidated financial statements for 2023 except for change in segment reporting. Pihlajalinna has changed its segment reporting from 1 January 2024. In the future, Pihlajalinna will have two reportable segments: Private Healthcare Services and Public Services. The new reporting structure follows Pihlajalinna's business model and organisational structure. More information on changed reporting segments is in Note 1.
The amended standards published by IASB to adopt in 2024 does not have a material impact on Pihlajalinna's financial reporting.
The information published in this Half Year Financial Report has not been audited. All figures have been rounded, due to which the actual total of individual figures may differ from the total presented. Key figures and figures reflecting changes have been calculated using the exact figures.
The alternative performance measures presented in this Half Year Financial Report should not be considered as replacements for the key figures defined in IFRS standards, and they may not be comparable with similarly named items used by other companies.
The preparation of the Half Year Financial Report in accordance with IFRS requires the management to make estimates and assumptions that affect the valuation of the reported assets and liabilities and contingent assets and liabilities on the statement of financial position, and recognition of the amount of income and expenses. Although the estimates are based on the management's best knowledge of current events and actions, the actual results may differ from the estimates provided in this Half Year Financial Report. The significant judgments made by management and the key accounting estimates and decisions based on management judgement were mainly the same as those that applied to the consolidated financial statements for the year 2023.
Pihlajalinna has changed its segment reporting from 1 January 2024. In the future, Pihlajalinna will have two reportable segments: Private Healthcare Services and Public Services. The new reporting structure follows Pihlajalinna's business model and organisational structure. Comparative data for the 2023 financial year was published with separate release on 24 April 2024. The comparable data is unaudited.
Private Healthcare Services operating segment consists of private clinic, diagnostics, hospital, occupational healthcare, remote and fitness center services. These comprehensive care path services are provided by Pihlajalinna to corporate customers, insurance companies, the public sector, and private customers through its nationwide network of medical centers and diverse digital channels.
Public Services operating segment consists of social and healthcare services produced primarily for the public sector, which include outsourcing and housing services, mainly remotely produced responsible doctor services, as well as a wide range of staffing and recruitment services.
In connection with the change, Pihlajalinna has carried out impairment testing on 31 March 2024, and goodwill has been allocated to cash-generating units in accordance with the new segment structure in the testing. The testing identified no impairment charges.
| Revenue, EUR million | 4–6/2024 | 4–6/2023 | change | 1–6/2024 | 1–6/2023 | change | |
|---|---|---|---|---|---|---|---|
| 3 months | 3 months | EUR | 6 months | 6 months | EUR | 2023 | |
| Private Healthcare Services | 112.3 | 105.9 | 6.4 | 226.9 | 218.5 | 8.4 | 423.1 |
| of which intersegment | 3.6 | 3.9 | -0.3 | 7.6 | 8.1 | -0.5 | 16.5 |
| Public Services | 66.1 | 81.9 | -15.8 | 138.8 | 161.7 | -22.9 | 314.3 |
| of which intersegment | 0.1 | 0.3 | -0.2 | 0.1 | 0.7 | -0.6 | 0.9 |
| Group total | 174.8 | 183.6 | -8.8 | 358.0 | 371.4 | -13.4 | 720.0 |
| Depreciation and impairment, EUR million | 4–6/2024 | 4–6/2023 | change | 1–6/2024 | 1–6/2023 | change | 2023 |
|---|---|---|---|---|---|---|---|
| 3 months | 3 months | EUR | 6 months | 6 months | EUR | ||
| Private Healthcare Services | -11.3 | -10.7 | -0.5 | -22.3 | -21.2 | -1.2 | -43.0 |
| Public Services | -1.9 | -2.1 | 0.2 | -3.8 | -4.2 | 0.4 | -8.9 |
| Group total | -13.1 | -12.8 | -0.3 | -26.1 | -25.3 | -0.8 | -51.9 |
| Share of profit in associated companies and joint ventures, EUR million |
4–6/2024 | 4–6/2023 | change EUR |
1–6/2024 | 1–6/2023 | change EUR |
2023 |
|---|---|---|---|---|---|---|---|
| 3 months | 3 months | 6 months | 6 months | ||||
| Private Healthcare Services | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 |
| Public Services | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.6 |
| Group total | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.5 |
| EBITA, EUR million | 4–6/2024 | 4–6/2023 EUR 3 months |
change | 1–6/2024 6 months |
1–6/2023 6 months |
change EUR |
|
|---|---|---|---|---|---|---|---|
| 3 months | 2023 | ||||||
| Private Healthcare Services | 6.2 | 5.3 | 0.9 | 16.6 | 14.4 | 2.2 | 26.7 |
| Public Services | 5.2 | 1.7 | 3.5 | 9.4 | 5.1 | 4.3 | 2.1 |
| Group total | 11.4 | 7.0 | 4.4 | 26.0 | 19.4 | 6.6 | 28.8 |
| EBITA, % | 4–6/2024 | 4–6/2023 | change | 1–6/2024 | 1–6/2023 | change | 2023 |
|---|---|---|---|---|---|---|---|
| 3 months | 3 months | 6 months | 6 months | ||||
| Private Healthcare Services | 5.5 | 5.0 | 0.6 | 7.3 | 6.6 | 0.7 | 6.3 |
| Public Services | 7.8 | 2.1 | 5.8 | 6.8 | 3.1 | 3.6 | 0.7 |
| Group total | 6.5 | 3.8 | 2.7 | 7.3 | 5.2 | 2.0 | 4.0 |
| Adjusting items affecting comparability, EUR million | 4–6/2024 | 4–6/2023 | change | 1–6/2024 | 1–6/2023 | change | |
|---|---|---|---|---|---|---|---|
| 3 months | 3 months | EUR | 6 months | 6 months | EUR | 2023 | |
| Private Healthcare Services | 0.0 | 0.4 | -0.4 | 0.3 | -0.5 | 0.8 | 0.5 |
| Public Services | 0.0 | -0.1 | 0.2 | 0.0 | -0.6 | 0.6 | 8.5 |
| Group total | 0.0 | 0.3 | -0.3 | 0.3 | -1.1 | 1.4 | 9.0 |
| Adjusted EBITA, EUR million | 4–6/2024 | 4–6/2023 | change | 1–6/2024 | 1–6/2023 | change | 2023 |
|---|---|---|---|---|---|---|---|
| 3 months | 3 months | EUR | 6 months | 6 months | EUR | ||
| Private Healthcare Services | 6.2 | 5.7 | 0.5 | 16.9 | 13.8 | 3.0 | 27.2 |
| Public Services | 5.2 | 1.6 | 3.6 | 9.4 | 4.5 | 5.0 | 10.6 |
| Group total | 11.4 | 7.3 | 4.1 | 26.3 | 18.3 | 8.0 | 37.8 |
| Adjusted EBITA, % | 4–6/2024 | 4–6/2023 | change | 1–6/2024 | 1–6/2023 | change | 2023 |
|---|---|---|---|---|---|---|---|
| 3 months | 3 months | 6 months | 6 months | ||||
| Private Healthcare Services | 5.5 | 5.4 | 0.1 | 7.4 | 6.3 | 1.1 | 6.4 |
| Public Services | 7.9 | 1.9 | 6.0 | 6.8 | 2.8 | 4.0 | 3.4 |
| Group total | 6.5 | 4.0 | 2.6 | 7.3 | 4.9 | 2.4 | 5.2 |
Reconciliation of the segments total adjusted operating profit before amortization and impairment of intangible assets (EBITA) to the consolidated profit before taxes
| EUR million | 4–6/2024 3 months |
4–6/2023 3 months |
change EUR |
1–6/2024 6 months |
1–6/2023 6 months |
change EUR |
2023 |
|---|---|---|---|---|---|---|---|
| Profit before taxes | 6.7 | 2.4 | 4.3 | 16.9 | 9.9 | 7.0 | 8.2 |
| Net financial expenses | 2.8 | 2.5 | 0.4 | 5.3 | 5.5 | -0.2 | 12.4 |
| Amortisation and impairment of intangible assets | 1.9 | 2.0 | -0.2 | 3.8 | 4.0 | -0.3 | 8.2 |
| Adjustment items | 0.0 | 0.3 | -0.3 | 0.3 | -1.1 | 1.4 | 9.0 |
| Adjusted EBITA | 11.4 | 7.3 | 4.1 | 26.3 | 18.3 | 8.0 | 37.8 |
Pihlajalinna reports its sales revenue divided into the following geographical regions:
| EUR million | 1–6/2024 | 1–6/2023 | change % | 2023 |
|---|---|---|---|---|
| Southern Finland | 77.9 | 72.4 | 7.5 % | 140.8 |
| Mid-Finland | 200.2 | 231.4 | -13.5 % | 445.9 |
| Western Finland | 20.0 | 19.7 | 1.7 % | 38.2 |
| East Finland | 32.5 | 29.7 | 9.5 % | 57.0 |
| Northern Finland | 27.3 | 25.0 | 9.4 % | 49.0 |
| Other operations | 36.4 | 32.2 | 13.0 % | 65.2 |
| Intra-Group sales | -36.3 | -38.9 | -6.8 % | -76.1 |
| Consolidated revenue | 358.0 | 371.4 | -3.6 % | 720.0 |
Pihlajalinna's customer groups are corporate customers, private customers and public sector customers.
either social and healthcare outsourcing services or residential, occupational healthcare and staffing services. The number of people within the scope of the Group's occupational healthcare services is approximately 95,000 in the public sector customers group.
| EUR million | 4–6/2024 | 4–6/2023 | change | change % |
|---|---|---|---|---|
| Corporate customers | 71.7 | 66.8 | 4.9 | 7.3 % |
| of which insurance company customers | 36.4 | 33.0 | 3.4 | 10.3 % |
| Private customers | 28.1 | 26.1 | 2.0 | 7.8 % |
| Public sector | 92.1 | 110.0 | -17.9 | -16.3 % |
| of which complete outsourcing agreements |
56.2 | 74.0 | -17.9 | -24.1 % |
| of which staffing | 6.9 | 7.7 | -0.8 | -9.8 % |
| of which occupational healthcare and other services |
29.0 | 28.3 | 0.7 | 2.5 % |
| Intra-Group sales | -17.1 | -19.3 | 2.2 | -11.3 % |
| Total consolidated revenue | 174.8 | 183.6 | -8.8 | -4.8 % |
Revenue from corporate customers amounted to EUR 71.7 (66.8) million, an increase of EUR 4.9 million, or 7.3 per cent. Sales to insurance company customers increased by EUR 3.4 million, or 10.3 per cent. Occupational healthcare services sales increased.
Revenue from private customers amounted to EUR 28.1 (26.1) million, an increase of EUR 2.0 million, or 7.8 per cent. The streamlining of insurance companies' payment authorizations and direct payment practices reduces reported sales to private customer segment.
Revenue from the public sector amounted to EUR 92.1 (110.0) million, a decrease of EUR -17.9 million, or - 16.3 per cent. The termination of cost liability for demanding specialised care in the wellbeing services county of South Ostrobothnia and Central Finland, the Jämsä Terveys' gradual transfer of services to the wellbeing services county and other changes to outsourcing agreements decreased revenue by EUR -19.3 million. The decrease was compensated by the annual price increases to complete outsourcing agreements and increase in occupational healthcare services sales.


| EUR million | 1–6/2024 | 1–6/2023 | change | change % |
|---|---|---|---|---|
| Corporate customers | 148.3 | 136.6 | 11.7 | 8.5 % |
| of which insurance company customers | 76.9 | 69.6 | 7.4 | 10.6 % |
| Private customers | 54.6 | 54.8 | -0.3 | -0.5 % |
| Public sector | 191.4 | 218.9 | -27.5 | -12.6 % |
| of which complete and partial outsourcing agreements |
118.0 | 146.6 | -28.6 | -19.5 % |
| of which staffing | 14.4 | 14.5 | -0.1 | -1.0 % |
| of which occupational healthcare and other services |
59.0 | 57.8 | 1.2 | 2.1 % |
| Intra-Group sales | -36.3 | -38.9 | 2.6 | -6.8 % |
| Total consolidated revenue | 358.0 | 371.4 | -13.4 | -3.6 % |
Revenue from corporate customers amounted to EUR 148.3 (136.6) million, an increase of EUR 11.7 million, or 8.5 per cent. Sales to insurance company customers increased by EUR 7.4 million, or 10.6 per cent. Occupational healthcare services sales increased.
Revenue from private customers amounted to EUR 54.6 (54.8) million, a decrease of EUR -0.3 million, or - 0.5 per cent. The divestment of dental care services at the end of March decreased revenue from private customers by EUR -4.1 million. The streamlining of insurance companies' payment authorisations and direct payment practices reduces reported sales to private customer segment.
Revenue from the public sector amounted to EUR 191.4 (218.9) million, a decrease of EUR -27.5 million, or -12.6 per cent. The termination of cost liability for demanding specialised care in the wellbeing services county of South Ostrobothnia and Central Finland, the Jämsä Terveys' gradual transfer of services to the wellbeing services county and other changes to outsourcing agreements decreased revenue by EUR -32.3
million. The decrease was compensated by the annual price increases to complete outsourcing agreements and increase in occupational healthcare services sales.


| EUR million | 4–6/2024 | 4–6/2023 | change, % | 1–6/2024 | 1–6/2023 | change, % | 2023 |
|---|---|---|---|---|---|---|---|
| Materials | -7.6 | -8.0 | -5.3 | -14.5 | -16.1 | -10.0 | -31.2 |
| Change in inventories | -0.1 | 0.4 | -129.8 | 0.1 | 0.3 | -72.7 | 0.2 |
| External services, practitioners | -34.4 | -32.0 | 7.5 | -70.5 | -67.3 | 4.8 | -129.8 |
| External services, other | -8.5 | -26.9 | -23.9 | -18.6 | -50.3 | -22.4 | -94.3 |
| Total | -50.6 | -66.4 | -12.6 | -103.5 | -133.3 | -12.9 | -255.2 |
| EUR million | 4–6/2024 | 4–6/2023 | change, % | 1–6/2024 | 1–6/2023 | change, % | 2023 |
|---|---|---|---|---|---|---|---|
| Wages and salaries | -67.6 | -68.6 | -0.8 | -137.4 | -136.9 | 0.7 | -267.1 |
| Share-based incentive schemes | |||||||
| - implemented as shares | -0.4 | 0.0 | -0.4 | 0.0 | -0.3 | ||
| Pension costs - defined contribution plans | -11.6 | -11.5 | 0.3 | -23.3 | -23.4 | -0.3 | -45.5 |
| Other social security expenses | -1.8 | -2.7 | -32.3 | -3.4 | -5.3 | -35.5 | -9.9 |
| Total | -81.4 | -82.8 | -32.8 | -164.6 | -165.7 | -0.6 | -322.8 |
At the beginning of 2022, the Board of Directors approved the terms of a share-based incentive program (LTIP 2022) for the key persons of the company. In its entirety the incentive scheme is to form a six- year program and the share rewards based on the program are not allowed to be disposed of prior to year 2026. In addition, to participate the in the program, a key person must invest in Pihlajalinna shares.
The performance and quality-based share programme comprises of four separate performance periods of one year each (the calendar years 2022, 2023, 2024 and 2025). The potential share rewards will be paid out after the performance periods in the years 2023, 2024, 2025 and 2026. The Board of Directors annually decides on the participants, performance indicators, targets and earning opportunities. The earnings criteria for the performance and quality-based share programme are Pihlajalinna Group's adjusted EBITA, as well as key operational, quality-related, and sustainability-related indicators. Three earnings periods have been launched under the programme: 2022, 2023 and 2024. For the earnings period 2024, a total of 42 key persons are entitled to participate to the share-based incentive programme.
The programme is treated in its entirety as equity-settled share-based payments. The maximum aggregate amount of share rewards that may be paid out based on the programme for earning periods 2024 and 2025 is approximately 575,000 shares (gross amount before the deduction of the applicable withholding tax) and the total value of the share rewards payable is approximately EUR 5.2 million. The above number of shares corresponds to approximately 2.5 per cent of the company's total number of shares.
| EUR million | 4–6/2024 | 4–6/2023 | change, % | 1–6/2024 | 1–6/2023 | change, % | 2023 |
|---|---|---|---|---|---|---|---|
| Facility expenses | -3.4 | -3.5 | -1.5 | -7.1 | -7.0 | 2 | -13.6 |
| Information management expenses | -6.6 | -6.7 | -1.9 | -13.3 | -13.5 | -1 | -26.3 |
| Sales and marketing expenses | -1.6 | -1.5 | 0.7 | -2.5 | -3.2 | -23 | -6.8 |
| Other expenses | -9.5 | -7.1 | 87.3 | -20.5 | -14.9 | 103.9 | -30.3 |
| Total | -21.0 | -18.8 | 11.8 | -43.4 | -38.5 | 13 | -77.0 |
| and impairment by asset type | |||||||
|---|---|---|---|---|---|---|---|
| EUR million | 4–6/2024 | 4–6/2023 | change, % | 1–6/2024 | 1–6/2023 | change, % | 2023 |
| Intangible assets | -1.9 | -2.0 | -9.6 | -3.8 | -4.0 | -6.2 | -8.2 |
| Property, plant and equipment | -3.4 | -2.8 | 18.9 | -6.7 | -5.7 | 17.8 | -12.0 |
| Right-of-use assets | -7.9 | -7.9 | -0.4 | -15.6 | -15.6 | 0.0 | -31.7 |
| Impairment | -0.6 | ||||||
| Total depreciation, amortisation and impairment | -13.1 | -12.8 | 2.4 | -26.1 | -25.3 | 3.0 | -51.9 |
| EUR million | 4–6/2024 | 4–6/2023 muutos, % | 1–6/2024 | 1–6/2023 muutos, % | 2023 | ||
|---|---|---|---|---|---|---|---|
| Interest expenses from financial liabilities carried at amortised cost |
-1.5 | -1.6 | -9.6 | -3.1 | -3.7 | -16.8 | -7.2 |
| Interest expenses on lease liabilities | -1.0 | -0.9 | 15.8 | -1.9 | -1.8 | 8.5 | -3.7 |
| Other financial expenses | -0.7 | -0.2 | 327.2 | -0.9 | -0.3 | 179.1 | -1.9 |
| Total | -3.2 | -2.7 | 19.7 | -5.9 | -5.8 | 1.7 | -12.7 |
| EUR million | 4–6/2024 | 4–6/2023 | change, % | 1–6/2024 | 1–6/2023 | change, % | 2023 |
|---|---|---|---|---|---|---|---|
| Current taxes | -1.4 | -1.1 | 28 | -2.8 | -3.5 | -21.6 | -0.5 |
| Deferred taxes | 0.2 | 0.5 | -51 | -0.7 | 1.3 | -155.0 | -3.0 |
| Total | -1.2 | -0.6 | 94 | -3.5 | -2.2 | 56.9 | -3.6 |
| EUR million | 30 Jun 2024 | 30 Jun 2023 | 2023 |
|---|---|---|---|
| Acquisition cost at beginning of period | 332.9 | 325.7 | 325.7 |
| Additions | 1.2 | 5.4 | 7.4 |
| Business combinations | 3.0 | 0.0 | 0.0 |
| Transfers between items | 0.0 | -0.1 | 0.0 |
| Reclassifications | 0.0 | 0.0 | 0.0 |
| Disposals | 0.0 | -0.1 | -0.2 |
| Acquisition cost at end of period | 337.0 | 330.9 | 332.9 |
| Accumulated depreciation at beginning of period | -60.0 | -51.9 | -51.9 |
| Depreciation and amortisation for period | -3.8 | -4.0 | -8.2 |
| Accumulated depreciation at end of period | -63.8 | -55.8 | -60.0 |
| Carrying amount at end of period | 273.2 | 275.0 | 272.8 |
| EUR million | 30 Jun 2024 | 30 Jun 2023 | 2023 |
|---|---|---|---|
| Acquisition cost at beginning of period | 142.6 | 123.6 | 123.6 |
| Additions | 7.3 | 15.8 | 19.0 |
| Transfers between items | 0.0 | 0.1 | -1.1 |
| Reclassifications | 0.0 | 0.0 | 0.0 |
| Disposals | -1.4 | 0.0 | 1.1 |
| Acquisition cost at end of period | 148.5 | 139.5 | 142.6 |
| Accumulated depreciation at beginning of period | -76.7 | -64.8 | -64.8 |
| Depreciation and amortisation for period | -6.7 | -5.7 | -12.0 |
| Transfers between items | 0.0 | -0.1 | 1.1 |
| Accumulated depreciation on disposals | 0.8 | 0.0 | -1.0 |
| Accumulated depreciation at end of period | -82.7 | -70.7 | -76.7 |
| Carrying amount at end of period | 65.8 | 68.8 | 65.8 |
| EUR million | 30 Jun 2024 | 30 Jun 2023 | 2023 |
|---|---|---|---|
| Acquisition cost at beginning of period | 371.0 | 320.0 | 320.0 |
| Additions | 11.5 | 15.9 | 39.6 |
| Transfers between items | 0.0 | 18.4 | 18.4 |
| Disposals | -5.5 | -6.3 | -7.0 |
| Acquisition cost at end of period | 377.1 | 348.0 | 371.0 |
| Accumulated depreciation at beginning of period | -167.1 | -122.2 | -122.2 |
| Depreciation and amortisation for period | -15.6 | -15.6 | -31.1 |
| Transfers between items | 0.0 | -18.4 | -18.4 |
| Accumulated depreciation on disposals | 1.0 | 3.8 | 4.6 |
| Accumulated depreciation at end of period | -181.7 | -152.4 | -167.1 |
| Carrying amount at end of period | 195.4 | 195.6 | 203.9 |
| EUR million | Right-of-use asset items 30 Jun 2024 | Lease liabilities 30 Jun 2024 |
|---|---|---|
| Carrying amount at beginning of period | 203.9 | 230.6 |
| Changes | 7.1 | 7.1 |
| Depreciation and amortisation | -15.6 | |
| Repayments of lease liabilities | -16.1 | |
| Carrying amount at end of period | 195.4 | 221.5 |
On 30 June 2024, EUR 202.9 million of the lease liabilities were the result of the adoption of IFRS 16 and EUR 18.6 million were financial lease liabilities in accordance with previous accounting standards.
| EUR million | Right-of-use asset items 30 Jun 2023 | Lease liabilities 30 Jun 2023 |
|---|---|---|
| Carrying amount at beginning of period | 197.7 | 229.6 |
| Changes | 13.4 | 13.7 |
| Depreciation and amortisation | -15.6 | |
| Repayments of lease liabilities | -15.8 | |
| Carrying amount at end of period | 195.6 | 227.4 |
On 30 June 2023, EUR 206.2 million of the lease liabilities were the result of the adoption of IFRS 16 and EUR 21.2 million were financial lease liabilities in accordance with previous accounting standards.
| 31 Jun 2024 | Fair value hierarchy |
Fair value through profit or loss |
Fair value - a hedging instrument |
Amortised cost |
Total carrying amounts |
Fair values total |
|---|---|---|---|---|---|---|
| Carrying amounts of financial assets | ||||||
| Non-current financial assets | ||||||
| Other shares and participations |
level 3 | 0.2 | 0.2 | 0.2 | ||
| Lease deposits | level 2 | 0.2 | 0.2 | 0.2 | ||
| Other receivables | level 2 | 0.1 | 0.1 | 0.1 | ||
| Loan receivables | level 3 | 2.2 | 2.2 | 2.2 | ||
| Current financial assets | ||||||
| Trade receivables | 49.0 | 49.0 | 49.0 | |||
| Interest derivatives | level 2 | 0.5 | 0.5 | 0.5 | ||
| Cash and cash equivalents | 13.0 | 13.0 | 13.0 | |||
| Total | 2.3 | 0.5 | 62.3 | 65.2 | 65.2 | |
| Carrying amounts of financial liabilities Non-current financial liabilities |
||||||
| Loans from financial | ||||||
| institutions | level 2 | 114.0 | 114.0 | 114.0 | ||
| Lease liabilities | level 2 | 191.2 | 191.2 | 191.2 | ||
| Other liabilities | level 2 | 0.5 | 0.5 | 0.5 | ||
| Contingent considerations | level 3 | 0.2 | 0.2 | 0.2 | ||
| Current financial liabilities | ||||||
| Loans from financial | ||||||
| institutions | level 2 | 2.0 | 2.0 | 2.0 | ||
| Contingent considerations | level 3 | |||||
| Lease liabilities | level 2 | 30.4 | 30.4 | 30.4 | ||
| Trade and other payables | 22.9 | 22.9 | 22.9 | |||
| Total | 0.2 | 361.0 | 361.2 | 361.2 | ||
| 31 Dec 2023 | Fair value hierarchy |
Fair value through |
Fair value - a hedging instrument |
Amortised cost |
Total carrying amounts |
Fair values total |
| Carrying amounts of financial assets | profit or loss | |||||
| Non-current financial assets | ||||||
| Other shares and | ||||||
| participations | level 3 | 0.2 | 0.2 | 0.2 | ||
| Lease deposits | level 2 | 0.2 | 0.2 | 0.2 | ||
| Other receivables | level 2 | 0.1 | 0.1 | 0.1 | ||
| Loan receivables | level 3 | 2.1 | 2.1 | 2.1 | ||
| Current financial assets | ||||||
| Trade receivables | 52.5 | 52.5 | 52.5 | |||
| Other receivables | level 2 | 0.2 | 0.2 | 0.2 | ||
| Interest derivatives | level 2 | 0.2 | 0.2 | 0.2 | ||
| Cash and cash equivalents | 24.5 | 24.5 | 24.5 | |||
| Total | 2.3 | 0.2 | 77.5 | 80.0 | 80.0 | |
| Carrying amounts of financial liabilities | ||||||
| Non-current financial liabilities Loans from financial |
level 2 | 143.8 | 143.8 | 143.8 | ||
| institutions | ||||||
| Lease liabilities | level 2 | 199.8 | 199.8 | 199.8 | ||
| Other liabilities | level 2 | 0.5 | 0.5 | 0.5 | ||
| Contingent considerations | level 3 | 0.2 | 0.2 | 0.2 | ||
| Current financial liabilities Loans from financial |
level 2 | 2.3 | 2.3 | 2.3 | ||
| institutions Contingent considerations |
level 3 | 0.7 | 0.7 | 0.7 |
| Trade and other payables | 27.1 | 27.1 | 27.1 | |
|---|---|---|---|---|
| Total | 0.9 | 404.3 | 405.2 | 405.2 |
Fair value hierarchy levels:
Level 1: Fair values are based on quoted prices in active markets for identical assets and liabilities. The Group has no financial assets or liabilities measured according to level 1 of the hierarchy.
Level 2: The fair value is determined using valuation methods. The financial assets and liabilities are not subject to trading in active and liquid markets. The fair values can be determined based on quoted market prices and deduced valuation. The carrying amount of the trade receivables and financial assets essentially corresponds to their fair value, as the effect of discounting is not significant taking the maturity of the receivables into consideration. The fair values of lease liabilities are based on discounted cash flows. The fair values of loans essentially correspond to their carrying amount since they have a floating interest rate and the Group's risk premium has not materially changed. The carrying amount of other financial liabilities essentially corresponds to their fair value, as the effect of discounting is not significant taking the maturity of the receivables into consideration. Derivative financial instruments are initially recognized at fair value on the trade date and are subsequently remeasured at their fair value on the balance sheet date.
Level 3: The fair value is not based on verifiable market information, and information on other circumstances affecting the value of the financial asset or liability is not available of verifiable. The Group's other shares and participations consist solely of shares in unlisted companies.
The Group monitors the amount of financing required by business operations by analysing cash flow forecasts to ensure that the Group has enough of liquid assets for financing operations and repaying maturing loans. The Group aims to ensure the availability and flexibility of financing with adequate credit limits, a balanced maturity profile and sufficiently long maturities for borrowings, as well as by obtaining financing through several financial instruments. The covenants included in the Group's financing arrangements are subject to continuous forecasting.
Pihlajalinna rearranged its long-term debt financing with a sustainability-linked financing arrangement in June 2024. The agreement includes a EUR 110 million term loan for refinancing the Group's previous debt, and a revolving credit facility of EUR 60 million for general financing purposes. The financing agreement is for three years and includes two option years.
The financing arrangement includes the customary financial covenants equivalent to the previous arrangement, concerning leverage (ratio of net debt to pro forma EBITDA) and gearing. IFRS 16 lease liabilities are not considered in the calculation of the covenants (Frozen GAAP). The loan margin of the financing is additionally linked to Pihlajalinna' s main sustainability targets: patient satisfaction, access to surgical treatment and employee engagement. Sustainability objectives have a minor effect on the loan margin, depending on how many of the agreed-upon sustainability targets are achieved.
The original gearing covenant of the financing arrangement is 115 per cent and the leverage covenant is 3.75. At the end of the review period, gearing in accordance with the financing arrangement was 75.8 per cent and leverage stood at 2.37.
Pihlajalinna issued EUR 20 million hybrid bond on 27 March 2023. The hybrid bond bears a fixed interest rate of 12.00 percent per annum until 27 March 2026 ("Reset Date"), and from the Reset Date, a floating interest rate as defined in the terms and conditions of the capital securities.
The hybrid bond is a subordinated instrument to the company's other debt obligations. The hybrid bond does not have a specified maturity date. Pihlajalinna is entitled to redeem the hybrid bond on the Reset Date and thereafter on each interest payment date. The hybrid bond will be treated as equity in Pihlajalinna's IFRS consolidated financial statements. The hybrid bond does not confer to the holders the rights
of a shareholder and do not dilute the holdings of the current shareholders. The net proceeds from the hybrid bond were used for the repayment of drawings under Pihlajalinna's existing revolving credit facility and for general financing purposes.
The Group has credit limit agreements valid until further notice, totalling EUR 10 million. The notice period of the credit limit agreements is one month. At the end of the review period, Pihlajalinna had EUR 70 million in unused committed credit limits. Unused credit limits consist of EUR 10 million credit limit agreement and EUR 60 million unused revolving credit facility.
The company has an interest rate swap agreement with a nominal value of EUR 65 million, which is used to convert the floating interest rate of the financing arrangement to fixed interest rate. Cash flow hedge accounting is applied to the interest rate swap agreement, which means that the effective portion of the change in fair value is recognised in other comprehensive income. The start date of the interest rate swap was in March 2023, and it is valid until 25 March 2027.
The table below presents the contractual maturity of financial liabilities. The figures are undiscounted, and they include both future interest payments and repayments of principal. In the table below, the loan instalments drawn under the Group's revolving credit facility are presented as long-term items despite their maturity being 1, 3 or 6 months, because Pihlajalinna has an unequivocal right to postpone the re-payment of the loan instalments by a minimum of 12 months from the reporting date. Interest payments related to the loan instalments drawn are presented in the table below according to the actual timing of their payment.
| EUR million | Carrying amount on 30 Jun 2024 |
less than 1 year | 1-2 years | 2-3 years | 3-4 years | over 4 years |
|---|---|---|---|---|---|---|
| Loans from financial institutions | 116.0 | -7.6 | -7.4 | -117.0 | -1.3 | -0.2 |
| Revolving credit facility | ||||||
| Lease liabilities | 221.5 | -34.2 | -31.1 | -27.0 | -25.1 | -123.8 |
| Other interest-bearing liabilities | 0.5 | -0.1 | -0.1 | -0.1 | -0.1 | -0.6 |
| Contingent considerations | 0.2 | 0.0 | -0.2 | |||
| Trade payables | 22.9 | -22.9 | ||||
| Total | 361.2 | -64.9 | -38.8 | -144.1 | -26.4 | -124.6 |
| EUR million | Carrying amount on 31 Dec 2023 |
less than 1 year | 1-2 years | 2-3 years | 3-4 years | over 4 years |
|---|---|---|---|---|---|---|
| Loans from financial institutions | 136.1 | -9.4 | -8.6 | -132.6 | -1.2 | -0.4 |
| Revolving credit facility | 10.0 | -0.5 | -0.5 | -10.2 | ||
| Lease liabilities | 230.6 | -34.5 | -31.4 | -26.3 | -23.7 | -134.5 |
| Other interest-bearing liabilities | 0.5 | -0.1 | -0.1 | -0.1 | -0.1 | -0.6 |
| Contingent considerations | 0.9 | -0.7 | -0.2 | |||
| Trade payables | 27.1 | -27.1 | ||||
| Total | 405.2 | -72.2 | -40.8 | -169.2 | -25.0 | -135.5 |
Pihlajalinna regularly reviews the credit risk of receivables and the procedures used to assess credit risk. No significant changes were observed in the payment behavior of customers during the review period.
The Group recognised impairment losses of EUR 0.5 (0.5) million on trade receivables during the review period. The Group recognised impairment losses of EUR 0.0 (0.0) million related to contract assets.
| EUR million | 30 Jun 2024 | 31 Dec 2022 |
|---|---|---|
| Trade receivables | 49.0 | 52.5 |
| Prepayments and accrued income | 8.7 | 4.7 |
| Current subleases | 0.4 | 0.4 |
| Other receivables | 0.0 | 0.2 |
| Contract assets | 3.1 | 3.6 |
| Total | 61.2 | 61.5 |
| EUR million | 30 Jun 2024 | of which written down |
Net 30 Jun 2024 |
31 Dec 2022 | of which written down |
Net 31 Dec 2022 |
|---|---|---|---|---|---|---|
| Not yet due | 35.7 | 0.0 | 35.7 | 34.3 | 0.0 | 34.3 |
| Past due | ||||||
| Less than 30 days | 8.4 | 0.0 | 8.4 | 12.9 | 0.0 | 12.9 |
| 30–60 days | 1.1 | 0.0 | 1.1 | 1.1 | 0.0 | 1.0 |
| 61–90 days | 0.7 | -0.1 | 0.6 | 0.6 | -0.1 | 0.5 |
| More than 90 days | 3.6 | -0.3 | 3.2 | 4.0 | -0.3 | 3.7 |
| Total | 49.5 | -0.5 | 49.0 | 52.9 | -0.5 | 52.5 |
On 1 May 2024, Pihlajalinna acquired full ownership of its former associated company Kuura Digilääkäri Oy. Pihlajalinna's previous holding in the company was 45 per cent. Pihlajalinna consolidates the company as an acquisition achieved in stages. The pre-existing interest in the acquiree was remeasured to fair value and the capital gain, amounting to EUR 78 thousand, was recognised in other operating income. The acquisition calculation is being finalised and will be completed within one year of the date of acquisition. A preliminary acquisition calculation is presented below:
| EUR million | 2024 |
|---|---|
| Consideration transferred | |
| Cash | 3.5 |
| Total acquisition cost | 3.5 |
The preliminary values of the assets and liabilities acquired for consideration at the time of acquisition were as follows:
| EUR million | 2024 |
|---|---|
| Trade and other receivables | 0.2 |
| Cash and cash equivalents | 0.5 |
| Total assets | 0.7 |
| Other liabilities | 0.1 |
| Total liabilities | 0.1 |
Preliminary goodwill generated in the acquisition:
| EUR million | 2024 |
|---|---|
| Consideration transferred | 1.9 |
| Previous holding measured at fair value | 1.6 |
| Net identifiable assets of acquirees | -0.5 |
| Preliminary goodwill | 3.0 |
| Transaction price paid in cash in the financial year | 1.9 |
| Cash and cash equivalents of acquirees | -0.5 |
| Effect on cash flow in the financial year | 1.4 |
The business combination generated preliminary goodwill of EUR 3.0 million. The goodwill generated is not taxdeductible. EUR 0.1 million in costs related to the acquisition has been recognised under other operating expenses (IFRS 3 costs). Revenue recognised as a result of the business combination for the review period in 2024 amounted to EUR 0.2 million, and the business combination had an effect of EUR 0.0 million on the result for the review period.
| EUR million | 30 Jun 2024 | 30 Jun 2023 | 2023 |
|---|---|---|---|
| Collateral given on own behalf | |||
| Sureties | 5.1 | 4.0 | 5.3 |
| Lease deposits | 0.2 | 0.6 | 0.2 |
| Properties' VAT refund liability | 0.0 | 0.0 | 0.0 |
| Lease commitments for off-balance sheet leases | 0.5 | 0.7 | 1.6 |
Investment commitments for the Group's development, additional and replacement investments amounted to approximately EUR 1.6 (2.2) million. The investment commitments are related to business premises investments, additional and replacement investments in clinical equipment and information system projects.
Pihlajalinna issued EUR 20 million hybrid bond on 27 March 2023. At the end of the review period, the unpaid interest was EUR 0.6 (0.6) million.
| EUR million | 1–6/2024 | 1–6/2023 | 2023 | |
|---|---|---|---|---|
| Key management personnel | ||||
| Rents paid | 0.6 | 0.5 | 1.0 | |
| Services procured | 0.6 | 0.6 | 1.3 | |
| Other Payments | 0.1 | 0.0 | 0.0 | |
| Prepayments | -0.1 | -0.1 | -0.1 | |
| Trade payables | 0.1 | 0.2 | 0.1 |
The Group has leased its business premises in Karkku, Tampere and Kangasala from Mikko Wirén's controlling company. Mikko Wirén is a member of the Group's Board of Directors. The Group also has an agreement with MWW Oy, a company controlled by Mikko Wirén, under which the Group buys healthcare professionals' services and consulting. In addition, during the review period the Group has paid old receivables, interest on late payment and premises renovation costs to a company controlled by Mikko Wirén.
| EUR million | Q2/24 | Q1/24 | Q4/23 | Q3/23 | Q2/23 | Q1/23 | Q4/22 | Q3/22 |
|---|---|---|---|---|---|---|---|---|
| INCOME STATEMENT | ||||||||
| Revenue | 174.8 | 183.2 | 183.0 | 165.6 | 183.6 | 187.8 | 188.4 | 165.2 |
| EBITDA | 22.7 | 25.7 | 11.6 | 20.1 | 17.7 | 23.0 | 11.5 | 18.1 |
| EBITDA, % | 13.0 | 14.0 | 6.4 | 12.1 | 9.7 | 12.3 | 6.1 | 10.9 |
| Adjusted* EBITDA | 22.7 | 26.0 | 20.7 | 20.5 | 18.0 | 21.4 | 12.0 | 18.9 |
| Adjusted* EBITDA, % | 13.0 | 14.2 | 11.3 | 12.4 | 9.8 | 11.4 | 6.4 | 11.4 |
| Depreciation and amortisation | -13.1 | -13.0 | -13.6 | -13.0 | -12.8 | -12.5 | -12.0 | -11.5 |
| Operating profit (EBIT) | 9.5 | 12.7 | -1.9 | 7.1 | 4.9 | 10.5 | -0.6 | 6.6 |
| Operating profit, % | 5.5 | 6.9 | -1.1 | 4.3 | 2.7 | 5.6 | -0.3 | 4.0 |
| Adjusted operating profit before the amortisation and impairment of intangible assets (EBITA) |
11.4 | 14.9 | 9.9 | 9.6 | 7.3 | 11.0 | 2.2 | 9.4 |
| Adjusted EBITA, % | 6.5 | 8.1 | 5.4 | 5.8 | 4.0 | 5.9 | 1.2 | 5.7 |
| Financial income | 0.4 | 0.2 | -0.1 | 0.2 | 0.2 | 0.1 | 0.4 | 0.1 |
| Financial expenses | -3.2 | -2.7 | -4.1 | -2.8 | -2.7 | -3.1 | -2.7 | -2.1 |
| Profit before taxes (EBT) | 6.7 | 10.2 | -6.1 | 4.4 | 2.4 | 7.5 | -2.8 | 4.5 |
| Income tax | -1.2 | -2.3 | -0.3 | -1.1 | -0.6 | -1.6 | 1.7 | -0.5 |
| Profit for the period | 5.5 | 7.9 | -6.4 | 3.3 | 1.8 | 5.9 | -1.1 | 4.0 |
| Share of the result for the period attributable to owners of the parent company |
4.8 | 7.2 | -5.2 | 3.5 | 2.0 | 5.5 | -0.7 | 3.3 |
| Share of the result for the period attributable to non-controlling interests |
0.7 | 0.8 | -1.2 | -0.2 | -0.2 | 0.4 | -0.4 | 0.8 |
| EPS | 0.19 | 0.30 | -0.25 | 0.13 | 0.07 | 0.24 | -0.03 | 0.14 |
| Average number of personnel (FTE) | 4,753 | 4,813 | 4,923 | 4,976 | 4,978 | 4,882 | 4,851 | 4,793 |
| Change in personnel during the quarter | -59 | -111 | -53 | -1 | 95 | 31 | 58 | -197 |
| Key figures | ||
|---|---|---|
| Profit for the financial period attributable to | ||
| owners of the parent company - | ||
| Earnings per share (EPS) | Hybrid bond interest expenses net of tax | |
| Average number of shares during the financial year | ||
| Alternative performance | ||
| measures | ||
| Equity attributable to owners of the parent com | ||
| Equity per share | pany | |
| Number of shares at the end of the financial period | ||
| Dividend distribution for the financial year (or | ||
| Dividend per share | proposal) | |
| Number of shares at the end of the financial period | ||
| Dividend/result, % | Dividend per share | |
| Earnings per share (EPS) | x 100 | |
| Effective dividend yield, % | Dividend per share | |
| Closing price for the financial year | x 100 | |
| P/E ratio | Closing price for the financial year | |
| Earnings per share (EPS) | ||
| Share turnover, % | Number of shares traded during the period | x 100 |
| Average number of shares | ||
| Return on equity (ROE), % | Profit for the period (rolling 12 months) | x 100 |
| Equity (average) | ||
| Return on capital employed, % | Profit before taxes (rolling 12 months) + financial | |
| (ROCE) | expenses (rolling 12 months) | |
| Total statement of financial position – non-interest | x 100 | |
| bearing liabilities (average) | ||
| Equity ratio, % | Equity | |
| Total statement of financial position - prepayments | x 100 | |
| received | ||
| Interest-bearing net debt - cash and cash equiva | ||
| Gearing, % | lents | x 100 |
| Equity | ||
| Operating profit + depreciation, amortisation and | ||
| EBITDA | impairment | |
| Operating profit + depreciation, amortisation and | ||
| EBITDA, % | impairment | x 100 |
| Revenue | ||
| Operating profit + depreciation, amortisation and | ||
| Adjusted EBITDA ¹⁾ | impairment + adjustment items | |
| Adjusted EBITDA, % ¹⁾ | Operating profit + depreciation, amortisation and impairment + adjustment items |
x 100 |
|---|---|---|
| Revenue | ||
| Adjusted EBITDA ¹⁾, excluding IFRS 16 |
Operating profit + depreciation, amortisation and impairment + adjustment items - IFRS 16 adjust ment |
|
| Net debt/Adjusted EBITDA ¹⁾, rolling 12 months |
Interest-bearing net debt - cash and cash equiva lents Adjusted EBITDA (rolling 12 months) |
|
| Net debt/Adjusted EBITDA, excluding IFRS 16, rolling 12 |
Interest-bearing net debt excluding IFRS 16 - cash and cash equivalents |
|
| months | Adjusted EBITDA, excluding IFRS 16 (rolling 12 months) |
|
| Cash flow after investments | Net cash flow from operating activities + net cash flow from investing activities |
|
| Adjusted operating profit (EBIT) ¹⁾ | Operating profit + adjustment items | |
| Adjusted operating profit (EBIT),% | Adjusted operating profit (EBIT) | |
| ¹⁾ | Revenue | x 100 |
| Adjusted operating profit before the amortisation and impairment of intangible assets (EBITA) ¹⁾ |
Operating profit + adjustment items + amortisation and impairment of intangible assets |
|
| Adjusted EBITA, % ¹⁾ | Adjusted operating profit before the amortisation and impairment of intangible assets (EBITA) Revenue |
x 100 |
| Profit before taxes (EBT) | Profit for the financial year + income tax | |
| Gross investments | Increase in tangible and intangible assets and in right-of-use assets |
|
| Comparable revenue for the previ ous period |
Revenue from the previous period - the effects of divestments to revenue - covid-19 services - other items affecting comparability |
|
| Comparable organic revenue growth |
Revenue for the period - comparable revenue for the previous period - revenue from M&A transactions |
| Comparable organic revenue growth, % |
Organic comparable revenue growth |
x 100 |
|---|---|---|
| Comparable revenue for the previous period |
¹⁾ Significant transactions that are not part of the normal course of business, are related to business acquisition costs (IFRS 3), are infrequently occurring events or valuation items that do not affect cash flow are treated as adjustment items affecting comparability between financial years. According to Pihlajalinna's definition, such items include, for example, restructuring measures, impairment of assets and the remeasurement of previous assets held by subsidiaries, the costs of closing down businesses and business locations, gains and losses on the sale of businesses, costs arising from operational restructuring and the integration of acquired businesses, costs related to the termination of employment relationships as well as fines and corresponding compensation payments. Pihlajalinna has also presented costs according to the IFRS Interpretations Committee's Agenda Decision concerning cloud computing arrangements, and reversals of amortisation, as adjustment items. Cloud computing arrangements costs and reversals of amortisation according to the IFRS Interpretations Committee's Agenda Decision has not been presented as adjustment items since 1 Jan 2024.
Pihlajalinna publishes a wide range of alternative performance measures, i.e. key figures that are not based on financial reporting standards, because they are considered to be significant for investors, the management and the Board of Directors in assessing the group's financial position and profitability. The alternative performance measures should not be considered to be replacements for the key figures defined in IFRS standards. The table below presents the reconciliation calculations for the alternative performance measures and the justifications for their presentation.
Reading notes:
| 4–6/2024 | 4–6/2023 | 1–6/2024 | 1–6/2023 | 2023 | |
|---|---|---|---|---|---|
| EUR million | 3 months | 3 months | 6 months | 6 months | |
| Return on equity (ROE), % | |||||
| Profit for period (rolling 12 months)/ | 10.3 | 10.7 | 4.6 | ||
| Equity (average) x 100 | 149.3 | 136.3 | 133.7 | ||
| Return on equity (ROE), % | 6.9 | 7.8 | 3.4 |
Return on equity is one of the most important indicators of a company's profitability used by shareholders and investors. The indicator illustrates the company's ability to look after the capital invested by shareholders in the company. The figure indicates how much return was accumulated on equity during the financial year.
| EUR million | 4–6/2024 | 4–6/2023 | 1–6/2024 | 1–6/2023 | 2023 |
|---|---|---|---|---|---|
| 3 months | 3 months | 6 months | 6 months | ||
| Return on capital employed (ROCE), % | |||||
| Profit before taxes (rolling 12 months) + | 15.2 | 11.6 | 8.2 | ||
| Financial expenses (rolling 12 months) | 12.9 | 10.6 | 12.7 | ||
| / | 28.0 | 22.2 | 20.9 | ||
| Total statement of financial position at beginning of period - | 657.5 | 661.6 | 661.6 | ||
| non-interest-bearing liabilities at beginning of period | 135.7 | 138.9 | 138.9 | ||
| 521.8 | 522.8 | 522.8 | |||
| Total statement of financial position at end of period - | 633.6 | 677.0 | 657.5 | ||
| Non-interest-bearing liabilities at end of period | 141.3 | 147.0 | 135.7 | ||
| 492.2 | 530.0 | 521.8 | |||
| Average x 100 | 507.0 | 526.4 | 522.3 | ||
| Return on capital employed (ROCE), % | 5.5 | 4.2 | 4.0 |
Return on capital employed is one of the most important indicators produced by financial statements analysis. It measures the company's relative profitability, or the return on capital invested in the company that requires interest or other returns.
| EUR million | 4–6/2024 3 months |
4–6/2023 3 months |
1–6/2024 6 months |
1–6/2023 6 months |
2023 |
|---|---|---|---|---|---|
| Equity ratio, % | |||||
| Equity/ | 154.1 | 149.8 | 144.6 | ||
| Total statement of financial position - | 633.6 | 677.0 | 657.5 | ||
| Advances received x 100 | 0.3 | 0.0 | 0.3 | ||
| Equity ratio, % | 24.3 | 22.1 | 22.0 |
The equity ratio measures the company's solvency, the capacity to tolerate losses and the ability to manage commitments in the long term. The indicator shows the percentage of the company's assets that are financed by equity.
| EUR million | 4–6/2024 3 months |
4–6/2023 3 months |
1–6/2024 6 months |
1–6/2023 6 months |
2023 |
|---|---|---|---|---|---|
| Gearing, % | |||||
| Interest-bearing financial liabilities – | 338.1 | 380.3 | 377.2 | ||
| Cash and cash equivalents/ | 13.0 | 26.1 | 24.5 | ||
| Equity x 100 | 154.1 | 149.8 | 144.6 | ||
| Gearing, % | 211.0 | 236.4 | 243.9 |
Gearing illustrates the company's indebtedness. The figure reveals the ratio between the equity invested in the company by shareholders and the interest-bearing debt borrowed from lenders.
| EUR million | 4–6/2024 3 months |
4–6/2023 3 months |
1–6/2024 6 months |
1–6/2023 6 months |
2023 |
|---|---|---|---|---|---|
| Net debt/adjusted EBITDA, rolling 12 months | |||||
| Interest-bearing financial liabilities - | 338.1 | 380.3 | 377.2 | ||
| Cash and cash equivalents | 13.0 | 26.1 | 24.5 | ||
| Net debt/ | 325.1 | 354.1 | 352.7 | ||
| Adjusted EBITDA (rolling 12 months) | 89.9 | 70.3 | 80.6 | ||
| Net debt/adjusted EBITDA, rolling 12 months | 3.6 | 5.0 | 4.4 |
This figure illustrates how quickly, at the current profit rate, the company would have paid off its debts if the EBITDA were to be used in full to repay the debts, if the company does not, for example, invest or distribute any dividend.
| EUR million | 4–6/2024 | 4–6/2023 | 1–6/2024 | 1–6/2023 | 2023 |
|---|---|---|---|---|---|
| 6 months | 6 months | ||||
| Interest-bearing net debt, excluding IFRS 16, % | |||||
| Interest-bearing financial liabilities excluding IFRS 16 – | 135.1 | 174.0 | 166.5 | ||
| Cash and cash equivalents/ | 13.0 | 26.1 | 24.5 | ||
| Equity x 100 | 161.0 | 154.6 | 150.5 | ||
| Interest-bearing net debt, excluding IFRS 16, % | 75.8 | 95.7 | 94.4 | ||
| EUR million | 4–6/2024 | 4–6/2023 | 1–6/2024 | 1–6/2023 | 2023 |
| Net debt/adjusted EBITDA, rolling 12 months, excluding IFRS 16 | |||||
| Interest-bearing financial liabilities excluding IFRS 16 - | 135.1 | 174.0 | 166.5 | ||
| Cash and cash equivalents | 13.0 | 26.1 | 24.5 | ||
| Net debt/ | 122.1 | 147.9 | 142.0 | ||
| Adjusted EBITDA excluding IFRS 16 (rolling 12 months) | 60.7 | 43.5 | 51.9 | ||
| Net debt/adjusted EBITDA, rolling 12 months, excluding IFRS 16 | 2.0 | 3.4 | 2.7 | ||
| EUR million | 4–6/2024 | 4–6/2023 | 1–6/2024 | 1–6/2023 | 2023 |
| 3 months | 3 months | 6 months | 6 months | ||
| EBITDA and Adjusted EBITDA | |||||
| Profit for period | 5.5 | 1.8 | 13.4 | 7.7 | 4.6 |
| Income tax | -1.2 | -0.6 | -3.5 | -2.2 | -3.6 |
| Financial expenses | -3.2 | -2.7 | -5.9 | -5.8 | -12.7 |
| Financial income | 0.4 | 0.2 | 0.6 | 0.3 | 0.4 |
| Depreciation, amortisation and impairment | -13.1 | -12.8 | -26.1 | -25.3 | -51.9 |
| EBITDA | 22.7 | 17.7 | 48.3 | 40.8 | 72.5 |
| IFRS 3 costs | 0.0 | 0.2 | 0.0 | 0.6 | 0.7 |
| Entries related to the IFRIC Agenda Decision concerning cloud computing arrangements |
0.3 | 0.7 | 1.0 | ||
| Other EBITDA adjustments | 0.0 | -0.2 | 0.3 | -2.7 | 6.4 |
| Total EBITDA adjustments | 0.0 | 0.2 | 0.3 | -1.4 | 8.1 |
EBITDA indicates how much is left of the company's revenue after deducting operating expenses. Assessments of whether EBITDA is sufficiently high should take into account the company's financial expenses, depreciation requirements and intended profit distribution. Adjusted EBITDA provides significant additional information on profitability by eliminating items that do not necessarily reflect the profitability of the company's operative business. Adjusted EBITDA improves comparability between periods and is frequently used by analysts, investors and other parties. The Group Management Team and operative management monitor and forecast adjusted EBITDA on a monthly basis.
| EUR million | 4–6/2024 | 4–6/2023 | 1–6/2024 | 1–6/2023 | 2023 |
|---|---|---|---|---|---|
| 3 months | 3 months | 6 months | 6 months | ||
| EBITDA, % | |||||
| EBITDA/ | 22.7 | 17.7 | 48.3 | 40.8 | 72.5 |
| Revenue x 100 | 174.8 | 183.6 | 358.0 | 371.4 | 720.0 |
| EBITDA, % | 13.0 | 9.7 | 13.5 | 11.0 | 10.1 |
| 4–6/2024 | 4–6/2023 | 1–6/2024 | 1–6/2023 | ||
| EUR million | 3 months | 3 months | 6 months | 6 months | 2023 |
| Adjusted EBITDA, % | |||||
| Adjusted EBITDA/ | 22.7 | 18.0 | 48.6 | 39.4 | 80.6 |
| Revenue x 100 | 174.8 | 183.6 | 358.0 | 371.4 | 720.0 |
| EUR million | 4–6/2024 3 months |
4–6/2023 3 months |
1–6/2024 6 months |
1–6/2023 6 months |
2023 |
|---|---|---|---|---|---|
| Profit for the period | 5.5 | 1.8 | 13.4 | 7.7 | 4.6 |
| Income tax | -1.2 | -0.6 | -3.5 | -2.2 | -3.6 |
| Financial expenses | -3.2 | -2.7 | -5.9 | -5.8 | -12.7 |
| Financial income | 0.4 | 0.2 | 0.6 | 0.3 | 0.4 |
| Operating profit (EBIT) | 9.5 | 4.9 | 22.2 | 15.4 | 20.6 |
| Entries related to the IFRIC Agenda Decision concerning cloud computing arrangements (reversal of amortisation ) - |
-0.1 | -0.3 | -0.5 | ||
| Other adjustments to amortisation and impairment | 0.1 | 0.2 | 0.9 | ||
| Total EBITDA adjustments | 0.0 | 0.2 | 0.3 | -1.4 | 8.1 |
| Total operating profit (EBIT) adjustments | 0.0 | 0.2 | 0.3 | -1.4 | 8.5 |
| Adjusted operating profit (EBIT) | 9.6 | 5.1 | 22.5 | 14.0 | 29.1 |
| PPA amortisation | 0.5 | 0.5 | 1.1 | 1.1 | 2.1 |
| Amortisation and impairment of other intangible assets | 1.3 | 1.6 | 2.7 | 3.2 | 6.6 |
| Entries related to the IFRIC Agenda Decision concerning cloud computing arrangements (reversal of amortisation) |
0.1 | 0.3 | 0.5 | ||
| Adjusted operating profit before the amortisation and impairment of intangible assets (EBITA) |
11.4 | 7.3 | 26.3 | 18.3 | 37.8 |
Operating profit indicates how much is left of the proceeds of actual business operations before financial items and taxes. With operating profit, the company must cover, among other things, financial expenses, taxes and the distribution of dividends. Adjusted operating profit provides significant additional information on profitability by eliminating items that do not necessarily reflect the profitability of the company's operative business. Adjusted operating profit improves comparability between periods and is frequently used by analysts, investors and other parties. The Group Management Team and operative management monitor and forecast adjusted operating profit on a monthly basis.
| EUR million | 4–6/2024 | 4–6/2023 | 1–6/2024 | 1–6/2023 | |
|---|---|---|---|---|---|
| 3 months | 3 months | 6 months | 6 months | 2023 | |
| Operating profit (EBIT), % | |||||
| Operating profit/ | 9.5 | 4.9 | 22.2 | 15.4 | 20.6 |
| Revenue x 100 | 174.8 | 183.6 | 358.0 | 371.4 | 720.0 |
| Operating profit (EBIT), % | 5.5 | 2.7 | 6.2 | 4.2 | 2.9 |
| EUR million | 4–6/2024 | 4–6/2023 | 1–6/2024 | 1–6/2023 | 2023 |
| 3 months | 3 months | 6 months | 6 months | ||
| Adjusted operating profit (EBIT), % | |||||
| Adjusted operating profit/ | 9.6 | 5.1 | 22.5 | 14.0 | 29.1 |
| Revenue x 100 | 174.8 | 183.6 | 358.0 | 371.4 | 720.0 |
| Adjusted operating profit (EBIT), % | 5.5 | 2.8 | 6.3 | 3.8 | 4.0 |
| 4–6/2024 | 4–6/2023 | 1–6/2024 | 1–6/2023 | ||
| EUR million | 3 months | 3 months | 6 months | 6 months | 2023 |
| Adjusted operating profit before the amortisation and impairment of intangible assets (EBITA), % |
|||||
| Adjusted operating profit before the amortisation and impairment of intangible assets (EBITA) / |
11.4 | 7.3 | 26.3 | 18.3 | 37.8 |
| Revenue x 100 | 174.8 | 183.6 | 358.0 | 371.4 | 720.0 |
| Adjusted operating profit before the amortisation and impairment of intangible assets (EBITA), % |
6.5 | 4.0 | 7.3 | 4.9 | 5.2 |
| EUR million | 4–6/2024 | 4–6/2023 | 1–6/2024 | 1–6/2023 | 2023 |
| 3 months | 3 months | 6 months | 6 months | ||
| Cash flow after investments | |||||
| Net cash flow from operating activities | 27.5 | 27.3 | 58.7 | 46.3 | 79.0 |
| Net cash flow from investing activities | -6.0 | -5.1 | -8.7 | -10.9 | -18.5 |
| Cash flow after investments | 21.6 | 22.3 | 50.0 | 35.4 | 60.5 |
Cash flow after investments (free cash flow) indicates how much cash is left for the company after deducting the cash tied up in operative business and investments. It indicates how much the company has left for its shareholders and creditors. Free cash flow indicates how sustainable the foundation of the company's profitability is, and it is used as the basis of the company's valuation.
| EUR million | 4–6/2024 3 months |
4–6/2023 3 months |
1–6/2024 6 months |
1–6/2023 6 months |
2023 |
|---|---|---|---|---|---|
| Profit before taxes | |||||
| Profit for period | 5.5 | 1.8 | 13.4 | 7.7 | 4.6 |
| Income tax | -1.2 | -0.6 | -3.5 | -2.2 | -3.6 |
| Profit before taxes | 6.7 | 2.4 | 16.9 | 9.9 | 8.2 |
| EUR million | 4–6/2024 3 months |
4–6/2023 3 months |
1–6/2024 6 months |
1–6/2023 6 months |
2023 |
| Gross investments | |||||
| Property, plant and equipment at end of period | 65.8 | 68.8 | 65.8 | 68.8 | 65.8 |
| Right-of-use assets at end of period | 195.4 | 195.6 | 195.4 | 195.6 | 203.9 |
| Other intangible assets at end of period | 18.5 | 22.3 | 18.5 | 22.3 | 21.1 |
| Goodwill at end of period | 254.8 | 252.7 | 254.8 | 252.7 | 251.8 |
| Depreciation, amortisation and impairment for period are added | 13.1 | 12.8 | 26.1 | 25.3 | 51.9 |
| Property, plant and equipment at beginning of period | 65.0 | 62.8 | 65.8 | 58.7 | 58.7 |
| Right-of-use assets at beginning of the period | 195.4 | 201.2 | 203.9 | 197.7 | 197.7 |
| Other intangible assets at beginning of period | 19.7 | 22.6 | 21.1 | 22.8 | 22.8 |
| Goodwill at beginning of period | 251.8 | 250.9 | 251.8 | 251.0 | 251.0 |
| Proceeds from the sale of property, plant and equipment during period |
-0.4 | 0.0 | -5.0 | -2.0 | -2.3 |
| Gross investments | 16.0 | 14.7 | 23.0 | 36.4 | 66.4 |
| 4–6/2024 | 4–6/2023 | 1–6/2024 | 1–6/2023 | |||
|---|---|---|---|---|---|---|
| EUR million | 3 months | 3 months | 6 months | 6 months | 2023 | |
| Comparable organic revenue growth, % | ||||||
| Revenue for previous period | 183.6 | 173.7 | 371.4 | 336.8 | 690.5 | |
| The impact of divestments on revenue during the period - | 0.0 | -4.7 | -4.8 | -4.7 | -12.0 | |
| Contractual changes in complete outsourcing agreements - | -19.3 | -5.7 | -32.3 | -11.4 | -32.1 | |
| Covid-19 services and write-down of revenue - | -0.2 | -3.0 | -0.5 | -13.5 | -18.0 | |
| Comparable revenue for previous period (B) | 164.1 | 160.4 | 333.8 | 307.3 | 628.4 | |
| Revenue from M&A transactions during period (C) | 2.9 | 14.1 | 16.2 | |||
| Revenue growth due to M&A transactions, % | 1.8 | 4.6 | 2.6 | |||
| Revenue for period (A) | 174.8 | 183.6 | 358.0 | 371.4 | 720.0 | |
| Comparable organic revenue growth (A-B-C) | 10.7 | 20.3 | 24.1 | 50.0 | 75.4 | |
| Organic revenue growth, % | 6.5 | 12.7 | 7.2 | 16.3 | 12.0 | |
| Revenue change | -8.8 | 9.9 | -13.4 | 34.6 | 29.5 | |
| Revenue change, % | -4.8 | 5.7 | -3.6 | 10.3 | 4.3 |
Organic growth of revenue refers to the growth of existing business that has not been achieved through mergers or acquisitions. Organic growth can be achieved by expanding service offerings, acquiring new customers, increasing visitation rates from existing customers, implementing price increases, and embracing digitalization. Public tenders won for healthcare outsourcing and self-established business locations are counted as organic growth. Comparable organic growth is calculated excluding the divestments, the transfer of cost liability for demanding specialised care, the gradual termination of Jämsän Terveys' service agreement, other changes to outsourcing agreements and COVID-19 services.
| EUR million | 4–6/2024 | 4–6/2023 | 1–6/2024 | 1–6/2023 | 2023 |
|---|---|---|---|---|---|
| EBITDA | 22.7 | 17.7 | 48.3 | 40.8 | 72.5 |
| Adjustments to EBITDA | |||||
| Dismissal-related expenses | 0.0 | 0.3 | 1.0 | 1.3 | |
| Costs arising from integration of acquired businesses | 0.1 | 0.2 | 0.2 | ||
| Classification of receivables as contingent assets according to IAS 37 | 7.8 | ||||
| Impairments on shares of interest in associates | 0.5 | ||||
| Gains on the sale of businesses | -0.1 | -3.6 | -3.6 | ||
| IFRS 3 costs | 0.0 | 0.2 | 0.0 | 0.6 | 0.7 |
| Entries related to the IFRIC Agenda Decision concerning cloud compu ting arrangements |
0.3 | 0.7 | 1.0 | ||
| Other items with cash flow effect | 0.1 | 0.1 | 0.3 | ||
| Other items with no cash flow effect | -0.1 | -0.2 | -0.1 | -0.2 | -0.2 |
| Adjustments to EBITDA in total | 0.0 | 0.2 | 0.3 | -1.4 | 8.1 |
| Adjusted EBITDA | 22.7 | 18.0 | 48.6 | 39.4 | 80.6 |
| Depreciation, amortisation and impairment | -13.1 | -12.8 | -26.1 | -25.3 | -51.9 |
| Adjustments to depreciation, amortisation and impairment | |||||
| Entries related to the IFRIC Agenda Decision concerning cloud compu ting arrangements (reversal of amortisation) |
-0.1 | -0.3 | -0.5 | ||
| Closure of operating locations | 0.1 | 0.2 | 0.2 | ||
| Impairments on investments | 0.6 | ||||
| Adjustments to depreciation, amortisation and impairment in total | -0.1 | 0.0 | 0.3 | ||
| Adjustments to operating profit in total | 0.0 | 0.2 | 0.3 | -1.4 | 8.5 |
| Adjusted operating profit (EBIT) | 9.6 | 5.1 | 22.5 | 14.0 | 29.1 |
| PPA amortisation | 0.5 | 0.5 | 1.1 | 1.1 | 2.1 |
| Other amortisation and impairment of intangible assets | 1.3 | 1.5 | 2.7 | 2.9 | 6.1 |
| Entries related to the IFRIC Agenda Decision concerning cloud compu ting arrangements (reversal of amortisation) |
0.1 | 0.3 | 0.5 | ||
| Adjusted operating profit before the amortisation and impairment of intangible assets (EBITA) |
11.4 | 7.3 | 26.3 | 18.3 | 37.8 |
| Operating profit (EBIT) | 9.5 | 4.9 | 22.2 | 15.4 | 20.6 |
| The adjustment items are presented in the income statement items as follows: EUR million |
4–6/2024 | 4–6/2023 | 1–6/2024 | 1–6/2023 | 2023 |
| Revenue | 2.1 | ||||
| Other operating income | -0.1 | -0.3 | -0.1 | -3.8 | -2.2 |
| Materials and services | 0.1 | 4.3 | |||
| Employee benefit expenses | 0.0 | 0.3 | 0.9 | 1.2 | |
| Other operating expenses | 0.1 | 0.5 | 0.1 | 1.5 | 2.2 |
| Share of profit in associated companies and joint ventures | 0.5 |
| EBITDA adjustment items total | 0.0 | 0.2 | 0.3 | -1.4 | 8.1 |
|---|---|---|---|---|---|
| Depreciation, amortisation and impairment | -0.1 | 0.0 | 0.3 | ||
| Operating profit (EBIT) adjustment items total | 0.0 | 0.2 | 0.3 | -1.4 | 8.5 |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.